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Abstract 
 
Hantaviruses are a group of rodent-borne viruses. Seoul hantavirus is considered to 
be the only global hantavirus, although reported human cases outside of Asia are 
rare. Human infection occurs when breathing in aerosols of excreta from infected 
rodents. Hantaviruses have been listed as a major impacting factor leading to a rise 
in acute kidney injury (AKI) throughout the Western world.  
In the UK, historically, there was evidence for human and animal exposure 
to hantaviruses demonstrated by the detection of specific antibodies and classic 
renal disease, however it is only during this study that existence of a UK hantavirus 
in wild rodent populations has been proven. Since 2012, several cases of acute AKI 
due to hantavirus infection in the UK have been confirmed. Two cases were from 
Yorkshire and had documented exposure to wild rats. Wild rodents were trapped 
from the farm belonging to one of the patient’s and a strain of Seoul virus, named 
Humber virus, was isolated from rats.  
Subsequent cases of AKI were in people with exposure to specially-bred pet 
fancy rats. Rats from one private breeding colony were tested and a second highly 
similar Seoul virus, named Cherwell virus, was described. Evidence for Cherwell 
virus was demonstrated in a human sample with genetic data of the virus 
recoverable from a serum sample. It was 100% identical to the pet rat strain, thus 
confirming SEOV as the causative agent of the patient’s AKI. These findings have 
implications for public health as Seoul virus is capable of causing moderate-severe 
human disease. The overarching aim of the thesis was to confirm hantaviruses cause 
human infection in the UK and raise clinical awareness; this was achieved. 
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CHAPTER 1 
Introduction 
 
Hantaviruses (genus Hantavirus, family Bunyaviridae) are a globally distributed 
group of RNA viruses. The genus derived its name from the prototype strain 
Hantaan virus (HTNV), first detected near the Hantaan River in Korea. Several 
distinct species are known to circulate; those confirmed to cause human disease 
within Europe are: Dobrava-Belgrade (DOBV), Puumala (PUUV), Saaremaa (SAAV) 
and Seoul (SEOV) viruses. Andes (ANDV) and Sin Nombre (SNV) are the 
predominant hantavirus species responsible for serious human disease in South and 
North America, respectively.  
 
Infectious virus particles are excreted in the urine, saliva and faeces of infected 
rodents.1 Human infection most often occurs when breathing in aerosols of 
infectious rodent excreta. In general, two clinical syndromes are recognised in 
severe cases: haemorrhagic fever with renal syndrome (HFRS) in Eurasia and 
hantavirus cardiopulmonary syndrome (HCPS) in the Americas.2 Historically known 
as a cause of ‘field nephritis’ in troops3, hantaviruses are now recognised as a 
zoonosis of public health importance and have been listed as one of the impacting 
factors leading to a rise in acute kidney injury (AKI) throughout the Western world.4 
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1.1  Classification 
Morphological analyses and molecular genomics led to the designation of 
hantaviruses within the family Bunyaviridae.5 The Bunyaviridae family was formally 
established in 1975 and contains five genera of viruses: Orthobunyavirus, 
Phlebovirus, Nairovirus, Topsovirus, and Hantavirus.6 Antigenic characterisation is 
used to separate the viruses within each genus. Arthropods, primarily mosquitoes, 
tick, and sand flies, are the predominant reservoirs for Bunyaviruses. Hantaviruses 
are the exceptions; these viruses are rodent-borne and are transmitted via 
aerosolised excreta.7 
  
1.2  Historical overview 
There are clinical reports in Chinese literature of maladies suggestive of hantavirus 
infection as early as 900 AD.8 Similar reports exist from England and France dating 
back to the 14th and 17th century, respectively.9 In more recent history, the disease 
was noted by Soviet researchers between 1913 and 1930 following sporadic 
outbreaks in Far Eastern USSR.10 Though unclassified at the time, it was during the 
Korean War that hantaviruses first gained international attention.11 United Nation 
troops suffered from symptoms including, fever, renal insufficiency, shock and 
haemorrhage. 12-14 The disease was initially termed Korean haemorrhagic fever 
(KHF); although a similar syndrome, termed epidemic haemorrhagic fever (EHF), 
had been recognised in China15, 16 and countries from the eastern former Soviet 
Union.10 Despite extensive investigation no aetiological agent was identified. It was 
not until 1976 that Lee et al (1978)17 demonstrated sera from KHF patients reacted 
with an immunofluorescence assay composed of tissue sections of Apodemus 
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agrarius (striped-field mice), but the sera did not react with sections from other 
rodent species. The virus was successfully isolated from infected A. agrarius and 
KHF patient samples and named Hantaan virus after the river from which the 
rodents were collected.17 Since then, all hantaviruses isolated have been named 
after the geographic locations in which they were discovered.  
 
Concurrently, a similar though clinically milder disease was recognised in 
Scandinavia18 and  Russia19 where it was known as nephropathia epidemica (NE)16 
Using the IFA method developed by Lee et al. (1978)17, reactive antibodies to HTNV 
were demonstrated in sera from NE and EHF patients from Scandinavia, Finland, 
Russia, China, eastern and western Europe.16, 20-24 Titres from samples obtained 
from Western Europe were lower than those from the rest of Asia, leading 
researchers to postulate that another hantavirus was responsible. Shortly 
afterwards a second hantavirus was isolated from Myodes glareolus (bank vole) 
captured in Puumala, Finland and therefore named Puumala virus.23  
 
Following the early years of research on HTNV in Korea it became evident that 
urban cases of hantavirus disease were occurring in Korea, China and Japan. 25, 26 
Sera tested positive for antibodies to hantavirus.27 Antigen was demonstrated in 
the lungs of Rattus norvegicus (brown rat) and Rattus rattus (black rat) trapped 
around Seoul, the capital city of South Korea. At the time the virus was initially 
presumed to be HTNV, it was later attributed to Seoul virus (SEOV).28 
 
Page | 14  
 
More hantaviruses continued to be discovered with the first New World hantavirus 
isolated from Microtus pennsylvanicus (meadow vole) in Maryland, USA and named 
Prospect Hill virus (PHV).29 Shortly after, two further hantaviruses were confirmed 
in Asia:  Thailand virus (THAIV)29 and Thottapalayam virus (TPMV).31,32 A second 
European hantavirus was detected; Dobrava-Belgrade virus was isolated from 
Apodemus flavicollis (yellow-necked mouse) which was later shown to cause severe 
human disease in Eastern Europe.33-35 
 
Electron microscopy of different hantavirus isolates at US laboratories revealed the 
morphology of a Bunyavirus.36-37 CDC  researchers went on to use Vero E6 cells for 
culture and neutralisation tests to confirm four distinct agents: HTNV, PHV, PUUV 
and SEOV.22 Hantavirus was proposed and accepted as a new name for this genus.38 
In 1983, all viruses serologically related to HTNV, and demonstrated to cause similar 
clinical symptoms, were categorised under the generic term haemorrhagic fever 
with renal syndrome.39  
 
A second human syndrome, hantavirus cardiopulmonary syndrome was 
documented in 1993 when Sin Nombre virus was discovered after 24 cases had 
been identified in the Four Corners region, USA. Antibodies to hantavirus were 
found and Peromyscus maniculatus (deer mouse) identified as the carrier of SNV.40 
This led to a new sub-group of hantaviruses characterised by severe disease with 
pulmonary and cardiac manifestations. Further investigation in the Americas led to 
the identification of Andes virus after it was noted that there was a high prevalence 
of hantavirus antibodies among native Americans in South America.41,42 This 
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hantavirus is unique in that there is strong evidence for human to human 
transmission.43  
 
The 2011 Ninth Report of the International Committee on Taxonomy of Viruses lists 
24 Hantavirus species (Table 1.1) with a comparable number proposed as 
candidates for future inclusion.44 It has been proposed that new Hantavirus species 
are only accepted on the list if the amino acid sequence differs by at least 10% for 
the S segment or 12% for the M segment from existing characterised species.45 
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Table 1.1 Hantavirus species accepted by ICTV listed according to their rodent host. 
 Virus Abbreviation Host species Common name 
Family: Cricetidae Subfamily: Arvicolinae (voles and lemmings from Eurasia and N America) 
Puumala PUUV Myodes glareolus bank vole 
Tula TULV Microtus arvalis European common vole 
Topografov TOPV Lemmus sibiricus lemming 
Khabarovsk KHAV Microtus fortis Maximowicz vole 
Prospect Hill PHV Microtus pennsylvanicus reed vole 
Isla Vista ISLAV Microtus californicus meadow vole 
Subfamily: Neotominae (mice and rats of the New World) 
Sin Nombre SNV Peromyscus maniculatus deer mouse 
New York NYV Peromyscus leucopus white-footed mouse 
El Moro canyon ELMCV Reithrodontomys megalotis western harvest mouse 
Rio Segundo RIOSV Reithrodontomys mexicanus Mexican harvest mouse 
Subfamily: Sigmodontinae (mice and rats of the New World) 
Andes ANDV Oligoryzomys longicaudatus long-tailed pygmy rice rat 
Bayou BAYV Oryzomys palustris marsh rice rat 
Black Creek Canal BCCV Sigmodon hispidus hispid cotton rat 
Cano Delgadito CADV Sigmodon alstoni Alston’s cotton rat 
Laguna Negra LANV Calomys laucha vesper mouse 
Muleshoe MULV Sigmodon hispidus hispid cotton rat 
Rio Mamore RIOMV Oligoryzomys microtis small-eared pygmy rice rat 
Family: Muridae Subfamily: Murinae (mice and rats of the Old World) 
Hantaan HTNV Apodemus agrarius coreae dark-striped field mouse 
Dobrava-Belgrade DOBV Apodemus flavicollis yellow-necked field mouse 
Saaremaa SAAV Apodemus agrarius agrarius striped field mouse 
Thailand THAIV Bandicota indica great bandicoot rat 
Seoul SEOV Rattus norvegicus, R. rattus brown rat, black rat 
Sangassou SANGV Hylomyscus simus African wood mouse 
Family: Sorcidae Subfamily: Corcidurinae and Soricinae (Insectivores) 
Thottapalayam TPMV Suncus murinus Asian house shrew 
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1.3  Virus structure and replication 
All Bunyaviridae have a negative-strand tripartite RNA genome composed of three 
segments (Figure 1.1). For hantaviruses this comprises the small segment (1530-
2078 nt) encoding the nucleocapsid (N) protein46, the medium segment (3534-3801 
nt) encoding a polyprotein which upon cleavage produces the glycoproteins Gn and 
Gc that embed in the virus membrane, and the large segment (6529-6578 nt) which 
encodes the RNA dependent RNA polymerase.47 The variable length of the three 
genome segments is mainly caused by the 3’ noncoding region. 
 
A putative non-structural protein NS has been described in hantaviruses associated 
with Arvicolinae (PHV, PUUV, TULV) and Sigmodontinae rodents (BCCV, ELMCV, 
SNV) but not for Murinae associated hantaviruses (DOBV, HTNV, SEOV).48 
 
For all three segments the 3’ terminal nucleotide sequence (AUCAUCAUCUG) are 
identical, conserved and complimentary to the 5’ terminal nucleotide sequence.46 
This leads to the formation of a panhandle structure thought to play a role in viral 
transcription and replication.49  
 
Electron microscopy studies demonstrate viruses belonging to the Bunyaviridae are 
spherical and generally have a diameter between 90 and 120 nm. Hantaviruses are 
however distinctive in the family due to their pleomorphic nature and have been 
demonstrated as tubular at different stages of replication ranging in size between 
70 and 210 nm.50, 51 
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Figure 1.1 Graphic illustration of a hantavirus virion containing three vRNPs: small, 
medium and large   
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1.4  Life cycle 
The hantavirus life cycle involves seven general processes: (1) attachment, (2) 
entry, (3) transcription, (4) translation, (5) replication, (6) assembly, and (7) progeny 
release. The glycoproteins facilitate attachment to and fusion with the host cell 
membrane, 52-54 thereafter cell entry occurs via receptor-mediated endocytosis.55 
Hantavirus replication takes place in macrophages and endothelial cells; particularly 
in the lungs and kidneys.45 Intracellular replication occurs exclusively in the 
perinuclear region of the cytoplasm of infected cells. After assembly of the 
structural proteins and genomic RNA into virus particles, the virions mature by 
budding in the Golgi complex.47, 56 The first newly formed virions can be detected 
within 24 hours post infection.56 
 
1.5  Relationship between hantaviruses and their natural hosts 
It took many years following the recognition of the resultant human disease to 
identify the reservoir of HTNV; a rodent, A agrarius. Until this isolation, all 
characterised viruses of the family Bunyaviridae were known to be arthropod-borne 
viruses. Each hantavirus is closely associated with a single (or a small number of 
closely related) Rodentia or Soricomorpha species.57  
 
Phylogenetic analysis of all available sequences for hantavirus species 
demonstrates the close affinity between virus and carrier species with distinct 
clades formed by the viruses maintained by Arvicolinae, Murinae and 
Sigmodontinae species regardless of the geographic origin of the sample.  
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The exact mechanism is not well understood but it is accepted that hantaviruses 
maintain persistent infections of their host rodent species through horizontal 
transmission. Regulatory T-cells have been suggested to mediate SEOV persistence 
in R. norvegicus.58 New-born animals are protected from infection by maternal 
antibodies transferred in utero.59 Once infected, rodents shed virus in their 
excretions including saliva, urine and faeces despite the presence of specific 
antibodies.60 Persistent infection in rodents is thought to occur with little or no 
pathogenic consequence but increasing evidence suggests that there are some 
detrimental effects. Weight gain and survival are reduced in SNV infected P. 
maniculatus.62, 63 Winter survival is reduced in PUUV infected My. glareolus64 and 
SEOV infected R. norvegicus demonstrate more aggressive behaviour than 
uninfected individuals.65 
 
Hantaviruses are able to survive and remain infectious on materials for several 
weeks in ideal conditions of low temperatures, moist conditions and little UV 
exposure.61 Other than inhalation of infectious particles, direct transfer by biting is 
thought be an important transmission route between rodents; this route is 
discussed further is section 1.16.4. 
 
1.6  Distribution 
Globally hantaviruses are an important cause of human illness with between       
150, 000 and 200, 000 cases of HFRS and approximately 200 cases of HPCS resulting 
in hospital admission annually.7 The majority of HFRS cases are reported from 
China, Korea, Russia and Scandinavia, followed by smaller numbers and sporadic 
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outbreaks in Japan, Central and Eastern Europe. The geographical distribution and 
pattern of human infections are driven by the natural rodent hosts for each 
hantavirus. The four hantaviruses responsible for the majority of clinical cases in 
Eurasia are DOBV, HTNV, PUUV, and SEOV.  
 
1.6.1 Dobrava-Belgrade virus 
DOBV causes a severe form of HFRS, however it is one of the most restricted 
hantaviruses in Europe with most cases reported from the Balkan region (Figure 
1.2) where its carrier host A. flavicollis is abundant. Due to the habitat preferences 
of A. flavicollis, cases are almost exclusively in rural forested locations.  
 
 
Figure 1.2 Current distribution of DOBV in Europe 
©Crown copyright and database rights 2014 Ordnance Survey 100016969/100022432 
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1.6.2 Hantaan virus 
HTNV, the most severe agent of HFRS, is established in China, Korea and eastern 
Russia where the common field mouse A. agrarius is the carrier rodent. Adults 
working and living in rural areas have the highest risk for infection.  
 
1.6.3 Puumala virus 
PUUV, the aetiologic agent causing the clinically the mildest form of HFRS, remains 
the most prevalent hantavirus in Western and Central Europe (Figure 1.3) where its 
carrier host My. glareolus is common; again with most cases occurring in rural 
locations.  
 
 
Figure 1.3 Current distribution of PUUV in Europe 
©Crown copyright and database rights 2014 Ordnance Survey 100016969/100022432 
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1.6.4 Seoul virus 
SEOV is an exceptional hantavirus due to its potential for global distribution via its 
carrier host, the brown rat, R. norvegicus, which is ubiquitous on every continent 
with the exception of Antarctica. With the opportunistic behaviour of R. norvegicus 
human cases occur in both rural and urban settings. Further information on SEOV is 
presented in section 1.16. 
 
1.7  Transmission 
Viral transmission to humans typically occurs when materials contaminated with 
rodent excreta are disturbed, causing virus particles to aerosolise and be inhaled. 
Contact between broken mucosal membranes and virus contaminated materials or 
through a direct bite are also potential routes of transmission.66 
 
Hantavirus infections in humans are reported throughout the year but often have 
seasonal peaks. In Scandinavia the majority of Puumala cases occur during winter 
when the rodent host, My. glareolus seeks shelter or food in human lodging. In 
contrast in Asia two peaks are evident - in spring and summer - related to planting 
and harvesting of crops which bring humans in close contact with rodents.67 
 
Mites have been found to be PCR positive for HTNV in China, and laboratory 
experiments have shown that direct and transovarial transmission is possible. 
Further research is required to prove such mechanisms are possible in a natural 
setting.68 
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With the exception of ANDV43 humans are dead-end hosts for hantaviruses. In 
1996, the first possible inter-human transmission cases of ANDV were suspected69 
with mounting evidence supporting limited human-to-human transmission for 
ANDV in health care workers and close family members.70 
 
1.8    Hantaviruses causing human disease 
While hantavirus infections in rodents are largely asymptomatic they can result in 
severe disease in humans. Two partly overlapping clinical syndromes have been 
described:  HFRS and HCPS.71 Hantaviruses carried by Sigmodontinae rodents 
generally cause more severe disease in humans than those carried by Murinae and 
Arvicolinae rodents.  
 
The incubation time is typically between 2 and 3 weeks but can be up to 8 weeks. 
Occupation is a dominant risk factor for hantavirus infection with animal workers, 
forestry workers, farmers and military personnel at greatest risk.7, 72 Infection 
occurs more often in males than females with ratios of 2:1 to 3:1 reported. Cases 
occur in all age groups however the highest incidence is in 20-40 year olds.73 
 
1.8.1  Haemorrhagic fever with renal syndrome 
As the name suggests HFRS is a disease characterised by vascular haemorrhage and 
kidney dysfunction. Disease can manifest as mild, moderate or severe with case 
fatality rates up to 15% depending on the causative virus.74 The initial symptoms 
have a rapid onset but are non-specific and include: intense headache, back and 
abdominal pain, fever, chills and nausea.71 Severe disease may manifest with low 
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blood pressure, acute shock, vascular leakage and acute kidney injury. Recovery of 
renal function usually occurs after 2-3 weeks although may take months; long-term 
impairment of renal function can occur75 as can hypertension.76, 77 Severe disease is 
more often associated with infection with HTNV or DOBV; moderate disease 
characterised by lower mortality but increased likelihood of liver involvement is 
associated with SEOV infection.78 PUUV infection results in the mildest form of 
HFRS and often leads to patients suffering from ocular manifestations.74 
 
1.8.2 Hantavirus cardio-pulmonary syndrome 
HCPS is characterised by acute onset of respiratory failure and cardiogenic shock. It 
bears resemblance to HFRS with vascular leakage, however the lungs are the 
primary target instead of the kidneys. In the early stages of disease non-specific 
symptoms such as fever, myalgia, malaise, headache and abdominal pain are 
indistinguishable from those of many other viral infections.71 This febrile stage lasts 
for up to 2 weeks, but typically less than 1 week. Patients may then go on to the 
cardiopulmonary stage and develop acute shortness of breath, dizziness and 
hypoxia followed by pulmonary oedema, myocardial dysfunction, hypoperfusion 
and shock.7 It is during this phase that the majority of HCPS patients die with 
mortality rates for HCPS higher than HFRS; rates are between 30 and 80% 
depending on the causative hantavirus. Patients who survive usually make a full 
though prolonged recovery with convalescence lasting several months during which 
time patients will experience fever and fatigue. 
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Table 1.2 Clinical Features of Clinically Relevant Hantaviruses7, 73  
Hantavirus ANDV DOBV PUUV SEOV HTNV SNV 
Severity Severe Severe Mild Moderate Severe Severe 
Renal damage ± +++ + + +++ ± 
Liver damage ± + No ++ + ± 
Lung damage +++ ++ No No + +++ 
Haemorrhage ± ++ ± + +++ ± 
Mortality 35% <10% <1% 1-2% 5-15% 35% 
± rarely reported; + some reports; ++ frequently reported, +++ often reported 
 
1.9 Non-pathogenic hantaviruses 
There are many hantaviruses that are yet to be linked to infection in healthy 
humans.7 Included in this list are the growing number of novel hantavirus species 
detected in Soricomorpha (shrews) 79-87 and Chiroptera (bats). 88-90 Of the rodent-
borne non-pathogenic hantaviruses in Europe, Tula virus (TULV) isolated from 
Microtus arvalis (European common vole) is the most likely candidate to be 
upgraded to a pathogenic species. While it has been associated serologically with 
human infection in the Czech Republic, Germany and Switzerland, it has not been 
unequivocally proven to cause human disease. 91-93 
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1.10 Pathogenesis 
Vascular dysfunction characterised by vasodilation and increased capillary 
permeability is thought to be the main factor in the pathogenesis of HFRS and 
HCPS. Both HFRS and HCPS are associated with rapid onset of thrombocytopenia 
and deranged vascular permeability and both can result in renal or pulmonary 
manifestations. Nevertheless, Old World hantaviruses predominantly result in renal 
dysfunction and the disease HFRS while New World hantaviruses are more 
frequently associated with cardiopulmonary failure - HCPS.  
 
In recent years, the paradigm of separating HFRS and HCPS has been challenged by 
multiple authors.94-100 Pulmonary symptoms including cough, pleural effusion and 
impaired pulmonary function have been reported for European cases of PUUV.100-
105 Acute kidney injury requiring dialysis has also been reported following SNV 
infection.97 It has been proposed that hantavirus infections be referred to as 
hantavirus disease instead of being divided into HFRS and HCPS, however this is yet 
to be widely adopted. 
 
It is widely accepted that human immunopathology, especially the cytotoxic T-
lymphocyte response, rather than direct viral cytopathology, drives 
pathogenesis.106-108 Host cells are not lysed by virions, as demonstrated by the lack 
of any visible CPE in endothelial cell culture.109,110 The N protein is the 
immunodominant antigen inducing an early humoral immune response, but it does 
not stimulate a neutralising antibody response.111,112 The formation of neutralising 
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antibodies and the protective immune response are instead induced by the 
glycoproteins.113  
 
Hantavirus specific IgM antibodies are rapidly produced following infection then 
decline to an undetectable level within 4 months.114 Specific IgG antibodies 
circulate shortly after infection and have been shown to persist for decades;  
providing life-long immunity as no re-infections have been reported.112-114 
 
Patient genetic make-up is considered to be important in predicting severe 
outcomes. Patients with the HLA B8 DR3 haplotype demonstrate high levels of viral 
RNA whereas patients with the HLA B27 allele are more likely to develop a lower 
viraemia and thus develop a milder form of PUUV disease.109 Integrins are cellular 
surface molecules commonly used by viruses as receptors for attachment and cell 
entry. They are expressed in many tissues including endothelial cells and platelets, 
which are thought to be the main targets during hantavirus infection. The usage of 
β3 versus β1 integrins for cell entry by hantaviruses seems to be an important 
pathogenicity determinant.115 The pathogenic hantaviruses, ANDV, HTNV, PUUV, 
SEOV and SNV use β3 integrins, whereas non-pathogenic hantaviruses PHV and 
TULV use β1 integrins. 
 
1.11 Treatment 
Therapy generally consists of supportive care with no specific treatment for HFRS or 
HCPS available at present. Both syndromes benefit greatly from careful fluid 
management and control of blood pressure. Dialysis may be necessary for severe 
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cases of HFRS, with between one and two sessions of haemodialysis needed before 
sufficient recovery of renal function.74 Mechanical ventilation is often required for 
HCPS patients with increasing evidence supporting the use of more aggressive 
support such as extracorporeal membrane oxygenation (ECMO) in severe cases.116 
Use of ECMO has been suggested to reduce long term complications.99 Death with 
HCPS is more often caused by cardiac failure than pulmonary oedema.117 
 
A lethal mouse model was developed for HTNV and utilised to show that ribavirin 
works by disrupting viral replication.118 Several years later human trials were 
performed in China that demonstrated ribavirin is successful at reducing viral load 
and improving outcome if given early in the disease progress.119 Ribavirin is 
itemised on the WHO Model List of Essential Medicines for HFRS treatment.7 
 
Due to the annual case burden and global distribution, efforts are on-going to 
develop an effective hantavirus vaccine. To date there is no WHO or FDA approved 
vaccine; however, there are two rodent brain and cell culture inactivated vaccines 
that have been developed and utilised in China and Korea.120, 121 Both are unlikely 
to gain widespread approval for use outside of Asia, with the most promising 
approach coming from a molecular approach using HNTV and PUUV plasmid DNA 
delivered by a gene gun.122, 123 
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1.12  Aetiological Diagnosis 
1.12.1 Serology 
Viraemia in humans suffering from HFRS, has a very short duration following onset 
of symptoms. Consequently, the diagnosis of hantavirus infection is typically made 
by the detection of hantavirus-specific antibodies. Serological techniques 
commonly used are immunofluorescence assays (IFA), enzyme linked 
immunosorbent assays (ELISA) and Western-blot analyses.124 The confirmation of 
an acute or recent hantavirus infection relies on the detection of hantavirus 
specific, IgM or a rise of IgG serum antibodies in paired samples. Even during early 
days of infection IgM, and usually, IgG antibodies are present.74 Due to the 
requirements for handling infectious ACDP hazard group 3 viruses and the lack of 
clinical isolates for the more novel hantaviruses, commercially available assays are 
almost exclusively based on recombinant hantavirus antigens.  The N protein, either 
in native or truncated form, is often the antigen of choice for serological assays due 
to its ability to induce early and long term antibody responses.125, 126 
 
Serological cross-reaction of antibodies between the different hantavirus species is 
a particular problem for diagnosis based solely on IFA and ELISA methods. 
Hantaviruses carried by the same rodent subfamily demonstrate the highest 
propensity to cross react: Murinae (DOBV, HTNV, SEOV), Arvicolinae (PHV, PUUV, 
TULV) and Sigmodontinae (ANDV, SNV).126-128 In most cases, it is almost impossible 
to differentiate between two closely related species using simply IFA or ELISA 
techniques. Differentiation of the causative species is often achieved by endpoint 
titration using focus reduction neutralisation assays however this technique is 
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limited to identification of the most closely related virus in the assay. In this 
instance FRNT is used to titrate antibodies in human serum against a panel of 
hantavirus; the one which is able to be titrated to the greatest dilution is 
considered to be the most likely infecting hantavirus species. However if the 
antibody response is to a novel hantavirus or a virus species simply not represented 
on the FRNT panel then the results may be misleading. Only molecular sequencing 
techniques can unquestionably identify the causative virus species.  
 
1.12.2 RT-PCR 
Reverse-transcriptase polymerase chain reaction (RT-PCR) is a sensitive and specific 
method for detection of viral RNA and is possible for most hantavirus species; 
however, it is rarely used as the sole diagnostic indicator for hantavirus infection.129 
Viral titre in human bodily fluids is typically low,130 thus a negative RT-PCR finding 
does not unequivocally provide a negative diagnosis.131 Nonetheless, RT-PCR does 
have its use in parallel with serological methods and, should a molecular signal be 
detected it will allow for exact identification of the causative species which can only 
be achieved by analysis of viral RNA.60,132 For human clinical samples nested RT-PCR 
is often necessary due to the low level of viraemia.133 RT-PCR is most successful 
with HCPS cases and when using sera collected within the first ten days of infection. 
 
1.12.3 Virus isolation 
The gold standard for clinical confirmation is isolation of the causative agent. For 
hantaviruses virus isolation from human clinical samples is time consuming, 
requires containment level 3 facilities and is rarely successful. Several hantaviruses 
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have been propagated in Vero E6 cells however primary isolation is difficult due to 
viral growth presenting no cytopathic effect instead establishing a non-cytolytic 
infection.134 
 
1.13  Control and Prevention 
Rodent control and the minimisation of human exposure to rodents and their 
excreta are among the most effective ways of reducing human disease. Rodent-
proofing of houses, food stores and careful removal of rodent waste are 
recommended control measures by the CDC.7 When cleaning rooms or disposing of 
rodent nest materials it is advisable to wear gloves, a protective mask and use 
bleach –based (hypochlorite) disinfectant.  
 
In the laboratory setting hantaviruses have been shown to be susceptible to 
inactivation via various methods including exposure to: acetone (100%), ethanol 
(70%), glutaraldehyde (2%), methanol (100%), paraformaldehyde (1%), sodium 
hypochlorite (1%) and UV irradiation.135 
 
1.14 Hantaviruses in the United Kingdom 
Laboratory confirmation of autochthonous and travel-related human hantavirus 
infection is provided by the Rare and Imported Pathogens Laboratory (RIPL), Public 
Health England (PHE), Porton Down. Due to the high levels of cross-reactivity 
between hantavirus species, and the lack of viral detection in any published United 
Kingdom (UK) study, it has previously been impossible to confirm and identify the 
presence of a single hantavirus species in the UK. Cases are likely to be under-
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reported due to mild cases presenting with non-specific symptoms and a lack of 
awareness of hantavirus infection as a potential diagnosis in the absence of travel.  
 
1.14.1 Potential carrier species 
Each hantavirus species is considered to have a specific rodent species acting as its 
natural reservoir, several of which are present in the UK including: R. rattus (rare, 
mainly in cities i.e. London, Liverpool) and R. norvegicus (ubiquitous)-SEOV; A. 
flavicollis (mainly southern England & Wales) - DOBV; My. glareolus (ubiquitous)- 
PUUV; and Mi. arvalis (Orkney)- TULV. There is also mounting evidence that rodents 
are not the only source of infection for humans with both non-rodent wild animals 
(deer, hare, shrew) and domestic animals (cat, dog, cattle) implicated.136 
 
1.14. 2 Serological evidence in animals 
Several studies have revealed evidence for circulation of hantaviruses in wild 
animals in the UK: one sero-survey of wild, feral and domestic cats from across 
England and Wales tested between 1983 and 1989 demonstrated antibodies 
reactive to HTNV (76-118).137 Overall 15 out of 157 (9.6%) domestic and feral cats 
were reported positive. From a further 198 chronically ill domestic cats, 30 (15.2%) 
had antibody to HTNV. Given their habit to kill and eat wild rodents, cats can be 
considered good sentinels for circulation of rodent-borne pathogens.  
 
1.14. 2 Serological evidence in rodents 
Studies examining rodent exposure continue to provide evidence for circulating of 
hantavirus in the UK. Antibodies against a panel of hantaviruses (HTNV, PUUV and 
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SEOV) were demonstrated in 4/100(4%)  R. norvegicus and 1/102 (0.98%) mice 
(species not stated) during an epidemiological investigation in rural Somerset, 
England in 1992.138,139 Furthermore, from 127 serum samples collected from R. 
norvegicus trapped on farms in Oxfordshire, North Wales and Hampshire, 5 (4%) 
had detectable  hantavirus-specific antibodies.140 Four of the samples reacted most 
strongly to SEOV (IR461) and one to HTNV (76-118). In 1996 similar results were 
demonstrated from Northern Ireland with antibodies against SEOV (R22) and HTNV 
(76-118) found among R. norvegicus (11/51 -21.6%) and A. sylvaticus (1/31 - 
3.2%).141  
 
1.14.3 Serological evidence in humans 
Since the 1980s there has been growing evidence for hantavirus as a cause of 
human disease in the UK. Sero-studies between 1985 and 1989 in England and 
Scotland suggest exposure in risk groups (residents in rural areas or with 
professions involving contact with rodents) ranging from 4.3% in sewage and water 
workers to 21.5% in farmers.142 At the time the sero-reactivity was considered to be 
PUUV-specific.  
 
In 1992 an in-depth regional study in Somerset, England, demonstrated IgG 
antibodies specific to hantavirus in 29 patients who were suffering from a flu-like 
illness between January and November.138 Symptoms described included: influenza-
like illness (67%), pyrexia (87%), headache (76%), abnormal liver function (62%) 
with severe cases also developing a sore throat, swelling of the face, neck, hands 
and lower limbs and a macular erythematous rash. A panel of three hantaviruses 
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were used for IFA screening: HTNV, PUUV and SEOV, however it is not clear from 
the reported results to which virus, if any, the predominant sero-reactivity was 
directed.  
 
The most recent sero-survey, published in 1999, discussed an investigation of 606 
farmers, farm workers and their families in Herefordshire and Lancashire, England 
and their exposure to a variety of zoonotic pathogens including hantaviruses.143 The 
authors reported a sero-prevalence of 4.7% during the first year of the study and 
4.8% in the second year.144 Again, a panel of hantaviruses was used for testing with 
no specific reactivity reported.  In terms of pinpointing an exact hantavirus species 
causing human disease in the UK in the absence of molecular data, McKenna et al 
(1994)145 provided the most conclusive serological evidence. Their sero-study of 
627 Northern Irish patients presenting with symptoms suggestive of HFRS and 100 
healthy controls found 16 patient samples (2.2%) reacted almost exclusively with 
SEOV (R22). 
 
1.14.4 Acute human cases 
Other than the symptomatic cases detected during the Somerset outbreak and 
during the Northern Ireland sero-study there have been eight other published cases 
of acute hantavirus infection most likely acquired in the UK.  Two were reported 
from Glasgow, Scotland, one in 1983 146, 147 and the other 1988, 148 five were 
reported during 1991, two from Sheffield, England148 and three from Somerset, 
England138,139,150,151 and one was reported from Nottingham, England during 
1994.152 Table 1.3 summarises the most common symptoms and laboratory 
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markers reported from these cases. Abdominal pain, raised creatinine, lowered 
platelets and a rash appear to be useful diagnostic indicators of HFRS disease in UK 
patients. Interestingly some case histories specifically mention recent contact with 
rats. Several of the cases were severe in nature, with renal replacement required, 
internal haemorrhage and hepatosplenomegaly occurring. All of the patients were 
otherwise healthy and had no recent travel history. 5/8 were male and 6/8 were 
aged 21 years old or under at the time of diagnosis.  
 
Table 1.3 Common symptoms reported from published case histories of UK HFRS 
patients. 
Symptoms/markers reported No. of patients Percentage of patients (%) 
Abdominal pain 6/8 75 
Proteinuria/elevated creatinine 6/8 75 
Rash 5/8 62.5 
Thrombocytopenia 4/8 50 
Fever 4/8 50 
Arthropathy 4/8 50 
Headache 3/8 37.5 
Vomiting 3/8 37.5 
Hepatosplenomegaly 2/8 25 
Acute kidney injury 2/8 25 
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1.14.5 Travel related cases 
There have been occasional imported cases of hantavirus infection into the UK. The 
first known case occurred in a British business man returning from Malaysia in 
1987.153 He suffered from typical symptoms including: fever, nausea, vomiting, 
thrombocytopenia and markers of renal impairment (elevated creatinine and 
proteinuria). While the sero-reactivity results were not disclosed, it is most likely to 
have been a SEOV or HTNV infection based on the geographical origin of infection. 
 
Several infections have been reported in British military personnel deployed to 
Bosnia in 1995154 and Slovenia in 2002.155 Symptoms and outcome were not shared 
for the three soldiers hospitalised in Slovenia but thought most likely to be due to 
DOBV infection. The case occurring in Bosnia required repatriation to the UK due to 
the patient’s serious condition. Typical symptoms of HFRS ensued; fever, abdominal 
pain, renal impairment, nausea and vomiting but less commonly severe pulmonary 
distress occurred. The patient, a 19 year old male, developed pulmonary oedema 
and required intubation and ventilatory support. A panel of hantavirus strains were 
used in the IFA for diagnosis; SEOV titres were reported as high as 1:3200 but the 
titres for other strains were not disclosed. Given our current knowledge and the 
severe course of disease for this patient it is more likely that he suffered from a 
DOBV infection. 
 
The most recent case prior to the commencement of this study occurred in a tourist 
during 2010, a 35 year old male, who had visited family in Estonia  3 weeks prior to 
his illness.156 His clinical course was milder than earlier travel-related cases however 
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typical symptoms ensued including headache, abdominal pain, fever and mild 
proteinuria, thrombocytopenia and raised creatinine. He also described blurred 
vision a symptom more typical of PUUV infection. This was further supported by 
epidemiological questioning which highlighted that he had visited a rural, forested 
area and had spent time in a barn used for food storage - a typical winter shelter 
area for the PUUV host My. glareolus. Sero-reactivity results confirmed this by 
demonstrating PUUV specific IgG antibodies at a titre of 1:4096.   
 
1.14.6 Laboratory related cases 
Hantaviruses are capable of infecting laboratory workers directly when they are 
exposed through incorrect handling of the virus or when infected tissues are 
processed. To reduce potential exposure, all manipulation of potentially hantavirus 
infected material is undertaken under UK containment level 3 conditions. Since all 
laboratory animal collections were sourced from wild colonies there is the 
possibility that laboratory workers may have been exposed to hantaviruses when 
handling potentially infected rodents or during manipulation of cell cultures set up 
from rodent tissues. One notable occurrence of this was reported in in 1979 when 
laboratory rats were identified as the source of HFRS cases in Japanese workers.157 
Once published, Belgian researchers tested samples from three workers who 
handled laboratory rats and were hospitalised with interstitial nephritis in 1978.158 
They confirmed antibodies reactive to HTNV with IFA and PRNT and concluded that 
their illness was likely to be due to hantavirus infection. Follow up of other workers 
at the Belgian institution found 48/391 (12.3%) workers who handled the rats had 
reactive antibodies. The outbreak was not limited to Japan and Belgium; in 1983 
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retrospective testing of UK workers at a Cancer Research Institute found 3/4 
workers (the fourth was unavailable for testing) who handled rats were sero-
positive using IFA.159 The three staff members were admitted to hospital in early 
1977, suffering from symptoms including: fever, abdominal pain, back pain, 
proteinuria, respiratory complications and renal insufficiency. Two of the patients 
required haemodialysis. The fourth untested staff member, although not admitted 
to hospital, was ill at home for 1 week. Six additional staff members who worked at 
the institute between 1975 and 1979 were retrospectively tested and four 
demonstrated antibodies. All exposures were linked to the Louvain (Lou C) inbred 
strain of rats developed from a strain of Wistar origin.160 The original colony had 
been imported from Japan via Belgium in 1975.161 All IFA slides used to confirm 
infections were HTNV cultured in E6 cells and therefore the virus was assumed to 
be a hantavirus strain. It was not until the UK isolate (IR461) was sequenced in 2003 
that it was reclassified as a strain of SEOV.162 One of a number of isolates (IR461) 
was one of a group of UK hantavirus that appeared to be genetically distinct from 
other SEOV strains. Following destruction of associated laboratory rat colonies and 
cell lines no further human cases were detected.  
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1.15  Rationale 
Prior to 2009 PUUV was considered to be the most likely hantavirus species 
responsible for HFRS cases in the UK due to the ubiquitous nature of its reservoir 
host and similar climatic conditions in the UK to PUUV endemic countries in 
Europe.163 It was not until 2009 that SEOV was again highlighted as the possible 
agent responsible for an HFRS in England. A patient suffering from AKI who 
reported a recent rat infestation in their residence was found to have reactive 
antibodies against hantaviruses. The purpose of this study was to investigate SEOV 
as the causative agent of human infection in England. 
 
1.16 Seoul hantavirus 
1.16.1 Reservoir host – R.  norvegicus  
SEOV is a unique hantavirus in that it is considered to have the potential for global 
distribution due to its reservoir host, R. norvegicus (Berkenhout, 1769) - the 
common brown rat or Norway rat - being ubiquitous on all continents with the 
exception of Antarctica. In the UK R. norvegicus is distinguished from other rodents 
by its larger size (body length 150- 270mm and weight 200-600g), brown-grey fur, 
pointed muzzle and long naked tail.  
 
In the wild they have an average lifespan of between 1 and 2 years; in captivity they 
may live as long as 4 years.164 Their preferred habitat includes agricultural land and 
human settlements, where they live in large, male dominated colonies with a 
typical territory of 2000 m2.165 R. norvegicus are mostly nocturnal and known to be 
neophobic which can lead to difficulty when attempting to trap or poison them. 
Page | 41  
 
They are excellent swimmers and often take up residence near waterways and take 
advantage of flooded areas. Breeding occurs throughout the year but increases 
during warmer months. Females are capable of producing seven litters per year of 
which there are approximately 8 pups per litter. Males reach sexual maturity at 3 
months old and females at 4 months. Originally this rat species was native to 
forests in what is now northern China and Mongolia. They arrived in Europe 
between the 16th Century and 18th Century.166, 167 They are considered a pest 
species and a prolific public health problem, with one British study linking them to 
13 zoonotic agents including hantaviruses.140 
 
Figure 1.4 Rattus norvegicus.  
Image credit http://spec-evo.wikia.com/wiki/File:Brown-rat.jpg  
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1.16.2  Human infection as a result of SEOV infection 
Worldwide, approximately 150,000 cases of HFRS are thought to occur each year; 
90% are reported from Asia168 of which 25% are a result of SEOV infection.169  With 
the global distribution of the reservoir host it is likely SEOV infections are under-
reported outside of Asia. Serological evidence for SEOV infection in humans has 
been demonstrated in Bosnia, 170 Brazil, 171 France, 172 Japan, 173 Northern Ireland, 
145 Russia174 and USA. Patients suffering from HFRS induced by SEOV have a shorter 
clinical course with milder renal dysfunction but more severe abdominal symptoms 
and hepatic dysfunction than those with HTNV infection.175 Symptoms reported 
from suspected European cases include: fever, myalgia, vomiting and diarrhoea, 
followed by acute renal failure and thrombocytopenia.145, 170, 172 
 
1.16.3 Evidence for SEOV outside of Asia 
Evidence for SEOV infection in rats has been demonstrated from Argentina,176 
Belgium,177,178 Brazil,171 Cambodia,179 Egypt,180 France,167 Indonesia,181 Japan,25 
North Korea,182 Portugal,183 Singapore,184 South Korea,185 Northern Ireland,141 
USA,186 and Vietnam.187 Antibody prevalence in wild rats ranges from 10% in 
Indonesia188 to 31.6% in Buenos Aires176 and 50% in Baltimore.189 In Europe, sero-
prevalence rates lie in-between those reported for Asia and America with 27% of 
rats antibody positive in Belgium177 and 21.6% of rats in Northern Ireland.141 
 
1.16.4 Transmission dynamics of SEOV 
The main transmission route for hantaviruses is inhalation of infectious particles; 
however, laboratory experiments have indicated SEOV to be more effectively 
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transmitted via intramuscular injections.190 Furthermore a correlation between 
presence of wounds and SEOV infection in wild rats has been observed.191,192 These 
findings suggest that biting is the main route of transmission for SEOV. As R. 
norvegicus is a long established animal species for scientific research several studies 
have been undertaken to better understand SEOV. Experimental infection 
investigating viral shedding revealed presence of virus in saliva, urine, faeces and 
blood/organs at 10, 20, 30 and 40 days post infection.193 Both sexes were equally 
susceptible to infection but male rats shed virus for longer, via more routes and 
also had higher levels of viral RNA in their blood.193,194 Sero-positivity has been 
shown to increase with rat body mass186 and age. Arikawa et al. (1986)195 reported 
that a higher proportion of Norway rats over six months of age were sero-positive 
(64%) compared with younger animals (9%) in Japan. Similar findings were found in 
rats positive for SEOV in Argentina.176  
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1.17  Aims 
Mounting evidence suggests that a hantavirus may be one of the infective causes of 
AKI in the UK. In the last four decades several acute cases in individuals without 
recent foreign travel have been detected and sero-prevalence studies in risk groups 
indicate continued exposure. Serological assays have been unable to determine the 
species of hantavirus responsible with atypical symptoms suggestive of more than 
one virus species or a novel virus circulating in the UK. Before commencement of 
this study no molecular evidence to confirm the causative species in wild rodents 
had been demonstrated, yet following the most recent case in 2009, SEOV was 
identified as the most likely agent. 
 
The overarching aim of this study was to investigate hantaviruses as a cause of 
clinical disease in England. The specific objectives were to: 
 identify and characterise a hantavirus circulating in rodents in the UK; 
 generate a cell culture isolate of a UK hantavirus; 
 confirm the hantavirus as a causative agent of human infection;  
 investigate  the extent of human exposure in key risk groups to the virus; 
 develop a serological diagnostic technique for identifying hantavirus  
infection outside of containment.  
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CHAPTER 2 
Materials and Methods 
 
Unless otherwise stated, all plastic consumables were sourced from Fischer 
Scientific (Loughborough, UK); tissue culture media, supplements, chemicals and 
antibodies were from Sigma-Aldrich (Gillingham, UK). All incubations occurred in a 
humidified 5% C02 atmosphere and samples were stored at -80 °C. Manipulations 
with suspected or confirmed hantaviral infectious material were performed in a 
class III microbiological safety cabinet (MSC III) under ACDP containment level 3 
(CL3) conditions at Public Health England (PHE), Porton Down in accordance with 
ACDP guidance on CL3 working practices. All molecular steps employed the use of 
nuclease free consumables.  
 
2.1  Rodent sampling 
2.1.1 Wild rodents 
Following confirmation of an acute human case of hantavirus with no travel history 
in January 2012, wild rodents were trapped and sampled from the patient’s 
residence in Yorkshire and the Humber, north-east England, UK during late 
February, early March 2012. A combination of live trapping (Longworth traps, 
Penlon LTD, Abingdon) and snap trapping (Rentokil snap traps) was employed. 
Traps were baited with sweet corn and peanut butter and checked twice per day to 
minimize stress on the animals. Live-trapped animal were humanely killed via 
cervical dislocation. Due to the high probability of exposure to infectious animals 
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and their excrement, personal protective equipment was utilised including: Tyvek 
suit, plastic boots, latex gloves, eye goggles and FFP3 mask. Disposables and waste 
were treated with 3% Virkon and transported as infectious clinical material. Animal 
carcases were packaged and transported according to HSE guidance for category B 
agents under the regulations for the Transport of Infectious Substances UN3373. 
 
2.1.2 Pet rodents 
After identification of domestic rats (Rattus norvegicus) as the likely source of a 
patient’s hantavirus infection in January 2013, sampling was undertaken in 
February 2013, at the site of the breeding colony where the rats originated from in 
Oxfordshire, south England, UK. Blood sampling of the lateral tail vein or via cardiac 
puncture immediately following euthanisation was undertaken by a veterinarian. 
Urine samples when available were collected by use of pastette. With consent of 
the owner, rats confirmed to be RT-PCR positive for SEOV RNA were euthanized 
with an intraperitoneal injection of sodium pentobarbitone (100 mg/kg) by a 
veterinarian.  
 
2.1.3 Processing of rodent samples 
Carcasses and samples were flash-frozen on solid carbon dioxide (C02) before being 
transported back to the laboratory under the same condition as described in 
section 2.1.1 for storage at -80 °C and necropsy. At dissection the following major 
organs were aliquoted individually: brain, bladder, heart, kidney, liver, lung, lymph 
node, pancreas, salivary gland and spleen.  A sample of each tissue in 500 µL sterile 
PBS was homogenised at 5000 rpm for 30 s (x2) using a MagNA Lyser instrument 
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and ceramic beads (Roche, West Sussex, UK). Tubes containing homogenate were 
centrifuged at 900 x g for 1 min and supernatant collected. Serum was separated 
from the blood using standard centrifugation (2300 x g for 15 min). 
 
2.2  RNA extraction 
2.2.1 RNA extraction from animal samples 
For purification of RNA from tissue, blood, serum and urine samples the samples 
were passed through QiaShredder columns (Qiagen, Manchester, UK) before using 
the Qiagen RNeasy Mini Kit in accordance with manufacturer’s instructions with the 
exception that infectious samples were inactivated in Qiagen AVL buffer instead of 
RLT buffer. In brief 140 µL of sample was added to 560 µL AVL and incubated for a 
minimum of 10 min within the MSC III.  Then 70% ethanol was added to the lysate 
and mixed before transferring the entire volume to the column and centrifuged at 
9500 x g for 1 min to bind RNA to the column filter. The column was washed with 
proprietary buffers RW1 and RPE with centrifugation repeated as previously 
between steps and an additional centrifugation after to remove buffer residue. RNA 
was eluted with 50 µL nuclease free water after a 1 min incubation and final 
centrifugation.  
 
2.2.2 RNA extraction from cell culture 
For isolation of total RNA from cells and culture supernatant the QIAmp Viral RNA 
Kit (Qiagen, Manchester, UK) was used in accordance with manufacturer’s 
instructions. In brief, 140 µL of sample was added to 560 µL AVL and incubated for a 
minimum of 10 min within the MSC III.  Pure ethanol was added to the lysate and 
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mixed before transferring entire liquid volume to column and centrifuged as 
previously described to bind RNA to the filter. The column was washed with 
proprietary buffers AW1 and AW2 with centrifugation between steps and an 
additional centrifugation step afterwards to remove buffer residue. RNA was eluted 
using 50 µL proprietary AVE buffer after a 1 min incubation and final centrifugation.  
 
2.3  Cells and viruses 
2.3.1 Cells 
Vero C1008 clone E6 (African green monkey epithelial kidney cell line: ECACC 
catalogue no. 85020205) cells were cultured at 37 °C in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) and 2 mM 
glutamine. Cells were sub-cultured after microscopic examination to ensure they 
were suitably confluent (80-90%) and free from bacterial or viral contamination. 
Cultures were routinely maintained in 75 cm2 and 175 cm2 filtered flasks. For 
routine passaging the growth medium was discarded and monolayer washed with 
PBS before a minimal volume of trypsin (0.25%) was added. The flasks were 
incubated for 5 min at 37 °C or until the cells visibly detached from the flask. Cells 
were mixed with new growth medium to produce an even suspension before being 
added to new culture flasks with a final split of between 1:3 and 1:10. Cultures 
were discarded after a maximum passage number of 30. 
 
2.3.2 Viruses 
All hantavirus strains (DOBV H119/99 0506241v, HTNV 76/118 0006112v, PUUV 851 
0504101v, SEOV R22 0107222v, SNV HN107 9908151v and TULV 0504102v) were 
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kindly provided by the National Collection of Pathogenic Viruses (NCPV), PHE, 
Porton Down. Stock virus was diluted 1:10 in serum-free DMEM and adsorbed to 
Vero E6 cells by incubation at 37 °C for 90 min with the flask rocked every 15 min to 
ensure even coating. Viral inoculum was removed and minimal fresh culture media 
added. Cultures were incubated at 35.5 °C for ten days. Virus was harvested by 
subjecting the flask to two freeze-thaw cycles at -80 °C to disrupt cells. Flask 
contents were then centrifuged at 900 x g for 10 min to pellet cellular debris. 
Supernatant was aliquoted and stored at -80 °C. 
 
2.4  Virus isolation 
SEOV real-time RT-PCR positive lung samples were used for virus isolation attempts. 
Homogenised tissue supernatant was diluted 1:10 with serum free DMEM, passed 
through a 0.45 μM filter and 2 mL added to sub-confluent (60%) cultures in 25 cm2 
flasks. Cells inoculated with 2 mL DMEM only acted as a negative control. Virus was 
left to adsorb for 90 min at 37 °C before inoculum was removed, minimal fresh 
culture media added and the culture incubated at 35.5 °C for between 12 and 14 
days. To minimise culture contamination from samples an antibiotic and 
antimycotic mix (2.5 μg/mL amphotericin B, 100 μg/mL kanamycin, 100 μg/mL 
penicillin streptomycin and 50 μg/mL gentamicin) was added to flasks at day 0, 5 
and 9. After 12-14 days, samples of culture supernatant and cells were added to 
AVL buffer for RNA purification and real-time RT-PCR analysis. Cells were detached 
with trypsin and 2 mL of cells added to fresh sub-confluent (60%) cultures in 25 cm2 
flasks. The addition of antibiotics and antimycotics was ceased after 3 passages. 
Remaining cells were used to prepare slides for immunofluorescence assay (IFA) 
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analysis, the method for which is described later in section 2.10.3. Isolations were 
considered unsuccessful if after 8 passages there were no positive RT-PCR results 
from extracted material (see section 2.5.1) or positive IFA signals (see section 
2.10.3) 
 
2.5  Polymerase Chain Reaction (PCR) 
2.5.1 One-step real-time RT-PCR  
Real-time RT-PCR was performed in a BioRad Mini Opticon cycler using SuperScript 
III Platinum One-step qRT-PCR kit (Life Technologies, Paisley, UK) and a modified 
version of a previously published real-time RT-PCR assay for the dual detection of 
HTNV and SEOV.128 The final master mix (20 µL) comprised 10 µL of 2X Reaction 
Mix, 0.9 µL of PCR-grade water, 1 µL of both a forward (5’-
CATGGCWTCHAAGACWGTGGG-3’ at 18 µM) and reverse primer (5’-
TTKCCCCAGGCAACCAT-3’at 9 µM), 0.3 µL of a single Minor Groove Binder (MGB) -
probe with a degenerate single base change (5’ FAM-TCAATGGGRATACAACT-3’ at 
25 µM) in place of the two non-degenerate published MGB-probes,  0.8 µL of 
SuperScript III RT/Platinum Taq Mix, 1 µL of MgSO4 and 5 µL of template. The 
cycling conditions used were 50 °C for 10 min, 95 °C for 2 min, followed by 45 cycles 
of 95 °C for 10 s, 60 °C for 40 s, with a final extension step at 40 °C for 30 s. The 
modification from a dual probe to a single probe arose during this study to reduce 
cost and reagents for each RT-PCR run. Nuclease free water was used for the 
negative control and viral RNA extracted from SEOV R22 culture used as positive 
control. Runs were repeated if either control did not perform as expected.  
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2.5.2 RT-PCR 
RT-PCR amplification was performed using SuperScript III One-Step RT-PCR System 
with Platinum Taq (Life Technologies, Paisley, UK). The final master mix (50 µL) 
comprised 25 µL of 2X Reaction Mix, 14 µL of PCR-grade water, 2 µL of both a 
forward and reverse primer (at 10µM working concentration), 2 µL of SuperScript III 
RT/Platinum Taq Mix, and 5µL of template. Cycling conditions were: reverse 
transcription step was 50 °C for 15 min then initial denaturation was at 94 °C for 2 
min followed by 45 cycles of; denaturation for 15 s at 94 °C, annealing for 50 s at 2 
°C below the lower Tm, and extension at 68 °C for 1 min per kb. A final extension 
step at 68 °C was 5 min for products less than 1kbp, or 7 min for longer products. 
Two published assays are described in Table 2.1: one targeting the S segment33 and 
a dual nested assay targeting the L segment.132 The S segment assay was the 
preferred method for rodent tissues due to the larger fragment length amplified for 
sequencing. This assay was unsuccessful at detecting specific RNA in any of the 
human samples tested due to the weak signal. For all human samples instead the 
nested assay was the method of choice. 
 
Table 2.1 List of RT-PCR primers used for pan hantavirus screening  
Target Use Name Primer sequence Tm °C Ref 
S Diagnostic  
pan-hanta 
HAN F 
HAN R 
GGC CAG ACA GCA GAT TGG 
AGC TCA GGA TCC ATG TCA TC 
61 
67 
34 
L Diagnostic  
1st pan-hanta 
HAN-L-F1 
HAN-L-R1 
ATG TAY GTB AGT GCW GAT GC 
AAC CAD TCW GTY CCR TCA TC 
55 
58 
133 
L Diagnostic  
nested pan-hanta 
HAN-L-F2 
HAN-L-R2 
TGC WGA TGC HAC IAA RTG GTC 
GCR TCR TCW GAR TGR TGD GCA A 
62 
64 
133 
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2.5.3 Electrophoresis of PCR products 
Amplified DNA products were visualised by agarose gel electrophoresis in Tris – 
borate – EDTA (TBE) (100 mM Tris, 90 mM boric acid, 1 mM EDTA) with ethidium 
bromide (0.5 µg/mL) and then visualised in 302 nm wavelength UV light using 
G:BOX  XT4 (Syngene, Cambridge, UK). Samples were loaded in 10x BlueJuice 
loading buffer (65% sucrose, 10 mM Tris-HCl, 10 mM EDTA, 0.3% bromophenol 
blue). Electrophoresis was carried out at 90 V for 45 min. Products were assessed 
against a quantitative 100 bp or 10 kb DNA ladder (New England BioLabs). Bands of 
interest were excised with a scalpel and purified using QIAquick Gel Extraction Kit 
(Qiagen, Manchester, UK) according to the manufacturer’s instructions. In brief, 
after excision bands were frozen at – 20 °C for a minimum of 60 min then thawed at 
room temperature. 3 X band volume of proprietary Buffer QC was added to each 
sample tube and incubated on a heat block at 50 °C until the agarose dissolved. 
Sample was added to QIAquick spin column and centrifuged at 9500 x g for 1 min.  
Flow through discarded and 500 µL of Buffer QC added to column, centrifuged as 
previously and discarded. A second wash step with 750 µL proprietary buffer PE 
was carried out before centrifugation of the sample column in a clean collection 
tube to ensure all flow through was discarded. The sample was eluted from the 
column with 50 µL nuclease free water. 
 
2.6  Sequencing of PCR products 
Sequence analysis was performed on viral RNA sourced directly from lung tissue or 
human sera using the same primers used to produce the amplicons and same 
cycling conditions as previously described in section 2.5.2 and Table 2.1 Nucleotide 
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labelling was carried out using Big Dye® Terminator v3.1 Cycle Sequencing Kit (Life 
Technologies, Paisley, UK), unincorporated dye terminator was removed using 
DyeEx 2.0 Spin Kit (Qiagen, Manchester, UK), and sequencing of products was 
carried out on a 3130xl sequencer (Life Technologies, Paisley UK) according to 
manufacturer’s instructions. FASTA nucleotide sequences were used as queries in 
BLASTN searches against the nucleotide collection database using the BLAST tool at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi.196 Following multiple nucleotide sequence 
alignments of available SEOV sequences in GenBank, primers were designed for 
each segment spanning overlapping intervals of ca. 500 bp as shown in Table 2.2. 
 
2.6.1 Sequence comparison and phylogenetic analysis 
The MEGA5 programme suite was used to perform alignments using ClustalW and 
phylogenetic analysis.197 Phylogenetic trees were constructed using the neighbour-
joining method, with bootstrap values obtained with 2,000 replicates from 
complete sequences available on GenBank (http://www.ncbi.nlm.nih.gov/genbank/ 
last accessed November 2014). 
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Table 2.2 List of PCR primers designed and used for Seoul virus sequencing 
Target Position Primer sequence (5’ – 3’) Tm °C 
S 1 + TAGTAGTAGRCTCCCTAAARAGCTA 53 
S 267 - GATGTTCTTCCCTGCTGCAATC 56 
S 374 - GTCAAGGCTATTCAGGTCCAGTG 57 
S 493 - AGTCTGCCTGCCTCTTGTTGTCA 60 
S 507 + GAGGATCAGATTCAAGGATGACAG 52 
S 596 - GCGTTTGGCATTGACACATACAG 68 
S 977 + CTGATAGGTGTCCACCAACAT 55 
S 1073 - GCCATAATTGTGTTCCTCATATCCTG 55 
S 1201 + ATGGTTGCCTGGGGAAAGG 68 
S 1530 + GCACAATCACTGCCATGTATAATC 54 
S 1534 + CTGCCATGTATAATCACGGG 62 
S 1588 - CCACCCTGTTCCCCATAYG 64 
S 1616 + GGATGTAGATTTCAATTGATCGAG 51 
S 1813 - TAGTAGTAGTATGCTCCTWAA 51 
M 1 + TAGTAGTAGACWCCGCAAGAAC 58 
M 222 - CTCTCTGGCACTAGCTGTTCTGC 59 
M 295 - CTTTCGCCATATGACCTTTGT 54 
M 420 - CTGATCTCCTGTTTCTATATG 47 
M 474 + GATTGTYCCWATWCATGCHTG 58 
M 572 - GTRGTRCARTAWGTYCTYTCRTAR 58 
M 1105 + GCACTYCCYTTRATYTGGAGGG 64 
M 1166 - GGRTGRAYTGCYTCATAGTAWCC 58 
M 1537 + CCTGCHTGYACATTRGCTRT 59 
M 1685 - CARATYTCACAHACCAKGARCC 58 
M 2158 - CWATRTGYARWGAKACACTYTGTTGRTC 59 
M 2047 + ATGCATACRGAYCTKGARTTWG 58 
M 2596 + ATGGAAGGAGGYGGWATWATC 58 
M 2672 - CCTRACATCACCAGGGTCTCC 64 
M 3097 + GAAAGTGDACACTNTCACGRGG 61 
M 3232 - CYARATGTGGDGCACTDGCYTG 62 
M 3274 + ATGATGATGGTGCACCTGAATG 55 
M 3406 + CCTGTTGAGCATTTTGTGTCCTG 56 
M 3656 - TAGTAGTAKRCTCCGCARRATGTC 57 
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Target Position Primer sequence (5’ – 3’) Tm °C 
L 1 + TAGTAGTAGACTCCGGAAGAGAC 57 
L 232 - TCCCAGCAAACAGCAATA 53 
L 441 - GAGATATCTCAGACCTCGCTC 53 
L 510 + GTAGTTGCAGTCCGGACAGA 62 
L 668 - CATTGCTTCTAGTGCAGCTC 60 
L 1038 + GCACATGATATGGCACACAGA 64 
L 1167 + ATGATGCGACCTGAGTCAAAG 64 
L 1281 - CTGATTGTACAATATGACTACTGATG 58 
L 1381 + GCTAAGTCAACATGAACCTCGAG 63 
L 1956 + CACTACTTGCAACAGCTACATGG 63 
L 2131 - GATGTCACAGCAGGTATCAGATA 60 
L 2745 + ATGTCAGGCCAAGTACAAGAGG 64 
L 2887 - CTAGCTTGTGCCTTCTGATGTC 62 
L 3144 + GGATACTTATGAACCTCATGTCAGAG 62 
L 3387 + GGGCATCATGGAGAGGTA 61 
L 3428 - GTTACCCTGCAACCAATTG 60 
L 3487 + CTGCATGAGCATATTCTTTTGC 63 
L 3678 - GCAGCTGCAAGATCATCG 63 
L 3812 + CCTTCTTGCTCACTATCTGACCTAC 63 
L 3943 - CTAAGTGAGACTGCAAGTTGTGAG 61 
L 4007 + CTGGTGAGACATTTCAGCAT 60 
L 4164 - GTAATCATATGTAGGATGCTGTTC 58 
L 4516 + GGGTAACATTTAGAGAGGTACTTGC 61 
L 4584 - CTTGTAACCAATAACAGCTGG 58 
L 4686 - GCTTTGTTGGTATCACATCACAG 63 
L 5195 + GTTYCATGCATTATGGTTTGAAG 61 
L 5280 - CTGGATCAATAGGAGGCACAC 63 
L 5780 + GCACAGTATGATGAAGATAGYCCA 61 
L 5850 - GCGAACATCACGGATAGTATG 61 
L 6263 + GGATGAGAGTGCTTATACAGGTG 61 
L 6318 + GGGTGAGTCTGTTGTGGATCA 57 
L 6422 - GATGTTAACTGGGTTGTATACCTTTTC 62 
L 6552 - TAGTAGTAGACTCCGCAAAATG 57 
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2.7  Virus ultracentrifugation 
Purified high-titre virus stocks were generated by culturing virus for 10 days in 175 
cm2 cell culture flasks. Virus was crudely harvested by subjecting the flask to two 
freeze-thaw cycles at -80 °C to disrupt cells. Flask contents were then centrifuged at 
900 x g for 10 min to pellet cellular debris. Supernatant was ultracentrifuged 
through a 20% sucrose cushion for 4 hours at 90, 000 x g. Virus pellets were 
resuspended in ice-cold TNE buffer (0.1 M NaCl, 0.001 M EDTA, 0.05 M Tris) by 
repeated vortexing. 
 
2.8  Inactivation of hantaviruses by UV irradiation 
Virus stock (0.5 mL) was placed in a plastic petri dish (Figure 2.1) and using a Bio-
Link BLX crosslinker (5 x 8-watt tubes), exposed to UV irradiation for 5 min at 312 
nm, equivalent to 1.4 J/cm2 as detailed by Kraus et al, (2005)135.  Inactivation was 
confirmed after 7 days of culture in Vero E6 cells where no detectable virus growth 
was demonstrated through in-house IFA as described in section 2.10.3. 
 
 
Figure 2.1 UV irradiation of hantaviruses 
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2.9  Fluorescent focus assay 
To determine virus titres of stocks a fluorescent focus assay was used; in brief, 
confluent Vero E6 cells grown in 48-well plates were inoculated with 100 µL virus 
per well in 10-fold dilutions (in PBS 2% FBS) from neat to 1:10,000. After virus 
adsorption for 90 min at 37 °C the cells were overlaid (1 mL overlay per well) with a 
1:1 mixture of 1.2% Avicel in demineralised water and 2X MEM supplemented with 
4% FBS. Plates were then incubated at 35.5 °C for 7 days. Virus was inactivated and 
cells fixed with 1 mL of 8% formaldehyde/PBS per well at 4 °C for a minimum of 60 
min. Wells were washed with PBS and residual liquid removed by inverting plates 
on tissue. Plates were permeabilised (0.5 mL 0.5% Triton-X100 and 20 mM 
glycine/PBS) for 30 min at room temperature to block residual aldehyde groups, 
and then washed with PBS. Staining was performed as described for in-house IFA 
section 2.10.3. For evaluation of the titres, the fluorescent focus units (FFU) of each 
well were counted and the titres calculated per mL. 
 
2.10  Immunofluorescence assays 
2.10.1 Commercial kits for human samples 
Sera were screened for presence of hantavirus IgG using a commercially available 
anti-hantavirus indirect immunofluorescence test mosaic 1 from Euroimmun 
(Luebeck, Germany) in accordance with the manufacturer’s recommendations. Each 
sample was compared to a known positive (Euroimmun CI 278h-0101-1G) and a 
negative control (human sera). The mosaic contains 6 biochips which allows for 
detection of antibodies against the most clinically relevant pathogenic hantavirus 
species (DOBV, HTNV, PUUV, SAAV, SEOV and SNV). Samples showing repeatable 
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characteristic cytoplasmic fluorescence at a dilution of 1:100 were considered 
positive. Where possible samples were titrated further up to 1:40,000. Where 
available a corresponding saliva sample for each positive serum sample was 
screened using the same assay and conditions. Slides were viewed at a total 200x 
magnification (10x eye piece and 20x lens) under blue-light using the manufacture’s 
recommended EUROStar III Plus microscope. Other commercial serological assays 
including an ELISA (Hantavirus IgG Dx Select; Focus Diagnostics, USA) and a strip 
immunoassay (RecomLine HantaPlus IgG; Mikrogen, Germany) were briefly 
evaluated in accordance with manufacturer’s instructions using control sera and 
deemed unsuitable due to and poor sensitivity and reproducibility. 
 
2.10.2 Commercial kit modified for rat sera  
Due to the high probability of rat sera containing infectious virus, blood samples 
were centrifuged inside of an MSC III in a CL3 laboratory and sera heat-inactivated 
at 60 ⁰C for 60 min. Serum samples were then tested using the Euroimmun IFA as 
previously described in section 2.10.1 with the exception of the secondary antibody 
being anti-rat IgG (whole molecule)-FITC produced in rabbit (F1763). 
 
2.10.3 In-house immunofluorescence slides 
Sub-confluent (80%), 75 cm2 Vero E6 culture flasks were washed with PBS and a 
minimal volume of trypsin (0.25%) added to disrupt the cell monolayer. Cells were 
pelleted in DMEM (no FBS) by centrifugation (900 x g for 10 min) and resuspended 
in 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS). The 
supernatant was discarded. Then 10 μL of cells were spotted onto glass slides and 
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cells allowed to settle and air dry before fixing with ice-cold 100% acetone for a 
minimum of 10 min. Negative and infected cells were stained with mouse 
monoclonal anti-Seoul N-protein antibody (R31- Progen, Heidelberg, Germany) at 
1:2 dilution, a secondary FITC-conjugated anti-mouse antibody (F8771) at 1:64 and 
counterstained with 0.1% Evans blue. Cultures were viewed at a total 200x 
magnification using EUROStar III Plus microscope. Infected cells were characterised 
by scattered, granular, punctate fluorescence when compared to negative control 
Vero E6 cells. 
 
2.11  In-house ELISA 
UV inactivated viruses: DOBV, HTNV, PUUV, SEOV, SNV and TULV (as described 
section 2.8) were used as the antigen for the ELISA. Protein estimation for each 
virus sample was performed using the NanoDrop 2000c (Thermo Scientific) 
Sufficient 96-well plates (Nunc MaxiSorp) were coated for 16 hours at 4 °C with 100 
µL of inactivated virus diluted ten-fold 1:10 - 1:10,000 in carbonate-bicarbonate 
buffer (pH 9.6). After coating wells were washed once with PBS 0.05 % Tween20 
and blocked for 60 min at 37 °C with BLOTTO Blocking Buffer (Thermo Scientific, 
Loughborough, UK). All subsequent wash steps were performed four times with 300 
µL PBS 0.05 % Tween20 per well and a final wash of only PBS. 100 µL of human sera 
confirmed positive for anti-SEOV or anti-PUUV IgG antibodies were used as primary 
antibody at 1:100 and 1:1000 dilution (diluted in BLOTTO buffer) and incubated for 
60 min at 37 °C. Human sera confirmed negative for anti-hantavirus antibodies was 
used a negative control. Wells were washed and 100 µL 1:20,000 anti-human IgG 
(whole molecule) - peroxidase antibody produced in goat (A8667) used as a 
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secondary antibody. The plate was incubated for 60 min at 37 °C after which wells 
were washed and 100 µL ABTS (Invitrogen, Paisley, UK) added and the plate 
covered in foil and incubated for 30 min at room temperature, followed by addition 
of 100 µL ABTS Peroxidase Stop Solution (Kirkegaard and Perry Laboratories, USA). 
Optical density (O.D.) of each well in the plate was measured at a wavelength of 
405 nm using an automated ELISA plate reader (Multiskan EX, Thermo Scientific). 
 
2.12  Sero-prevalence studies 
2.12.1 Farmers – prospective sero-study 
Subjects included in the study were adult volunteers (≥18 years old on day of 
sampling) who verbally confirmed they fitted the eligibility criteria which was: (1) 
must reside in North Yorkshire & Humber, (2) their main occupation is working on a 
farm or their main residence is within a farm, and (3) who had consented to blood 
donation for the purpose of anonymous screening for the presence of antibodies 
against hantavirus. Volunteers were provided with study information and a consent 
form before sample collection. A questionnaire (Appendix I) was completed by face 
to face interview.  
 
Sample size calculation was based on the most recent and comparable survey 
where 4.7% of farmers were sero-positive.143 A minimum sample size of 73 was 
calculated to be sufficient to estimate the proportion sero-positive, assuming the 
true prevalence is 5%, with 95% confidence level and 5% precision. As sampling was 
planned to occur at farmer meetings and markets, the sample size was recalculated 
to account for clustering assuming an intra-cluster correlation coefficient of 0.1 as 
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n1 = n(1 + p(m − 1)), where n is the estimated sample size assuming simple random 
sampling, n1 is the new estimate of the required sample size, p is the intra-cluster 
correlation coefficient and m is the number of clusters (here assumed to be 5). 
Hence, the revised sample size was approximately 100. 
 
The study was approved by NHS National Research Ethics Service reference 
05/Q2008/7. 
 
2.12.2 Military – retrospective sero-study 
Volunteers were recruited from either British Army regiments or Royal Marines 
units prior to deploying to Helmand, Afghanistan.  For each deployment, a research 
nurse visited the unit and presented study information to the troops.  Volunteers 
were required to give their informed consent and to have a single ‘pre-deployment’ 
blood sample taken.  Upon return from their six month tour of duty, volunteers 
were visited and asked to give a second ‘post-deployment’ blood sample. This study 
had Ethical Approval from both NHS National Research Ethics Service (reference 
05/Q2008/7) and MOD Research Ethics Committee. 
 
2.12.3 Renal patients – retrospective sero-study 
Samples included in the survey were adults (≥18 years old) admitted to Portsmouth 
Renal Unit during 2013 who had been clinically diagnosed with either acute kidney 
injury (AKI) or chronic renal failure (CRF) of undetermined aetiology. Patients were 
randomly selected and archived samples (stored at -20 °C) aliquoted anonymously 
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before shipping to PHE, Porton Down for testing. A date and diagnosis of AKI or CRF 
was provided with each sample. 
Sample size calculation was based on the most comparable survey where 
2.1% of renal patients in Northern Ireland were sero-positive.144 A minimum sample 
size of 207 was calculated to be sufficient to estimate the proportion sero-positive, 
assuming the true prevalence is 2.1%, with 95% confidence level and 2% precision. 
 
2.13  Human sera and saliva sampling 
Blood was collected by venepuncture (8 mL) and serum (2 - 4 mL) separated from 
the blood using standard centrifugation.198 Saliva was collected using the Salivette 
system (Sarstedt Ltd., Leicester, UK) with saliva separated as described by Lamey 
and Nolan (1994).199 Serum and saliva samples were stored frozen at −80 °C until 
tested.  
 
2.14  Data Processing and Statistical Analysis 
Statistical analyses were performed with the software program Minitab version 16 
(Minitab Inc., State College, PA, USA) and the R language for statistical computing 
(http://www.R-project.org). Fisher’s exact test was used to compare proportions 
when sample size was low and expected values ≤5. Significance was set at p < 0.05; 
95% confidence intervals for proportions were calculated using the Wilson 
Method.200 
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CHAPTER 3 
Characterisation of a UK hantavirus isolate and confirmation of a 
human pathogen 
 
3.1  Introduction 
In humans, the timeframe to detect viral nucleic acid in blood can be relatively 
short for certain infections including those caused by hantaviruses and detection by 
this route has rarely been successful as a diagnostic tool. In contrast carrier rodents 
are believed to be persistently infected and testing of their tissues offer the 
greatest opportunity for molecular characterisation of the infecting hantavirus 
species and strain. Taking this into consideration the study aims were to investigate 
rodents linked to recent human cases of hantavirus infection on the UK to 
determine and characterise the likely causative agent of infection. 
 
In addition to the acute human cases and serological evidence discussed in Chapter 
1, immediately prior to the commencement of this study, two acute human cases 
were diagnosed, one in Yorkshire and one in London with no recent travel history 
(pers. comm. Dr. Tim Brooks, PHE Porton).  One of the cases showed strongest 
reactivity with SNV and the other with SEOV. Upon epidemiological questioning the 
latter case from Yorkshire disclosed recent exposure to wild rats at his residential 
dwelling. 
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3.2  Hantavirus in Yorkshire – exposure to wild rats 
3.2.1 Detection of acute human infection 
In December 2011, a 59 year old man presented to his local Accident and 
Emergency Department with a history of fever, chills and a cough. The patient was 
a resident on a small livestock farm in North Yorkshire and Humber where he 
occasionally assisted with farm work, however his main occupation was office-
based. The patient disclosed regular exposure to rats on his home premises, where 
the rat population had increased in recent months. Two weeks prior to his visit to 
A&E, he had been prescribed flucloxacillin by his General Practitioner (GP) to treat a 
cut on his wrist which he acquired from falling on a metal pig ark at the farm.  
 
Following admission to the hospital’s Infectious Disease ward with suspected 
leptospirosis he was treated with intravenous benzylpenicillin and oral 
ciprofloxacin. Blood tests revealed deranged liver enzymes, lymphopenia, and 
thrombocytopenia and indicated AKI with creatinine peaking on day four, following 
admission, at 378 µmol/L (normal range 50-110 µmol/L). Physical examination 
demonstrated increasing lower abdominal pain. Tests for Legionella, Leptospira and 
hepatitis virus A, B, C and E were negative. Two serum samples submitted to RIPL at 
PHE Porton confirmed acute hantavirus infection with rising IgG titres across the 
majority of hantavirus species on the IFA (Figure 3.1). The highest titres were seen 
for SEOV and HTNV (Table 3.1) at 1:40, 000 and 1:20, 000 respectively. This was 
considered to be the second documented case of hantavirus infection in Yorkshire 
linked to rats. A full recovery was made and after two months all of the patient’s 
haematological and serum biochemical measurements had normalised. 
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Figure 3.1 Typical fluorescence pattern seen with presence of anti-SEOV IgG 
antibodies using Euroimmun mosaic 1 slides viewed at total 200x magnification 
using EUROStar III plus microscope 
 
Table 3.1 Results of patient’s hantavirus serology 
Hantavirus 06/01/12 18/02/12 
DOBV 1:1000 1:3200 
HTNV 1:10, 000 1:20, 000 
PUUV 1:1000 1:1000 
SAAV 1:1000 1:3200 
SEOV 1:10, 000 1: 40, 000 
SNV 1:100 1:1000 
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3.2.2 Wild rat sampling 
In February 2012, after obtaining permission, trapping of small mammals was 
commenced on the patient’s farm. Eleven rodents in total were dissected and their 
organs tested: five Apodemus sylvaticus (wood mouse), four R. norvegicus and two 
My. glareolus. Extracted RNA from each rodent lung was subjected to a genus-
specific RT-PCR assay targeting the S segment. Two R. norvegicus (RN1 and RN4) 
samples produced amplicons of the expected size of ca. 850 bp (Figure 3.2). RT-PCR 
of extracted nucleic acid from organs of the positive rats, found detectable RNA in 
the heart, lung, lymph node and salivary gland tissue of both rats, and the brain, 
bladder, kidney, liver, and spleen of one rat. No RNA was detected in the pancreatic 
tissue of either rat (Figure 3.3). The cDNA from both amplicons was sequenced and 
showed the highest level of similarity (97%) to Seoul hantavirus IR461 (GenBank 
accession no. AF329388) in a standard nucleotide BLAST analysis (NCBI/Blast 
http://blast.ncbi.nlm.nih.gov/Blast.cgi last accessed November 2014). Complete 
sequencing of all three segments directly from RN1 and RN4 lung tissue confirmed a 
SEOV. Detailed phylogenetic analysis is discussed in section 3.4. 
 
3.2.3 Family follow up 
Other family members and one farm worker were invited to be screened for 
exposure to hantaviruses. Seven in total volunteered: 4 females and 3 males. No 
hantavirus reactive IgG antibodies were detected in any of the serum samples using 
the standard IFA. 
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Figure 3.2 RT-PCR results of RNA extracted fromwild mammal lung tissue from 
Yorkshire farm 
 
 
Figure 3.3 RT-PCR results of RNA extracted from RN1 (top) and RN4 (bottom) 
individual organs. (1) DNA ladder, (2) brain, (3) bladder, (4) heart, (5) kidney, (6) 
liver, (7) lung, (8) lymph node, (9) pancreas, (10) salivary glands, (11) Spleen, (12) 
R22 positive control 
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3.3  Investigation in Oxfordshire – exposure to pet rats 
3.3.1 Detection of acute human infection 
In November 2012, a 28 year old man was admitted to hospital in North Wales with 
a four day history of fever, chills, diaphoresis and vomiting. Laboratory investigation 
revealed thrombocytopenia, deranged liver enzymes, AKI and hypoxia. His 
condition worsened and he required aggressive fluid replacement, 38 days of 
ventilatory support and 21 days of renal replacement therapy within the intensive 
care unit. A stored serum sample taken one month before admission (for an 
unrelated health event), and a sample taken whilst in the ICU confirmed a sero-
conversion to hantaviruses, specifically SEOV and HTNV (Table 3.2). After 52 days in 
hospital the patient made a full recovery and was discharged from hospital. 
 
Table 3.2 Results of patient’s hantavirus serology 
Hantavirus Oct 2013 Dec 2013 
DOBV Neg 1:1000 
HTNV Neg 1:10, 000 
PUUV Neg 1:100 
SAAV Neg 1:1000 
SEOV Neg 1: 10, 000 
SNV Neg 1:100 
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Epidemiological investigation identified pet agouti rats (R. norvegicus) kept by the 
patient’s partner as a probable source of infection. As the patient was unwell soon 
after his admission, the pet rats were returned to the care of the original breeder in 
Oxfordshire, south England.  
  
3.3.2 Pet rat sampling 
The two rats linked to the index patient were housed in a separate building to that 
of the breeder’s pet rat colony. A blood sample was taken by a veterinarian from 
the tail vein of the animals and a urine sample collected from one. All three samples 
were positive for hantavirus via real-time RT-PCR using a specific SEOV/HTNV dual 
MGB probe. The decision was made to euthanize the two rats with the permission 
of the owner and take blood samples from the breeder’s larger rat colony from 
which the two rats originated.  
 
Real-time RT-PCR and serology results, where available, are detailed in Table 3.3 In 
brief, 7 additional rats were found to be RT-PCR positive and 21/21 rats tested 
demonstrated IgG antibodies against SEOV and HTNV; 2 rats were unable to be 
tested. Dissection and RT-PCR analysis of individual organs from rat 001 
demonstrated extensive infection (Figure 3.4): Bladder, heart, kidney, liver, lung 
and lymph nodes had detectable RNA. Viral RNA sourced directly from lung tissue 
was subjected to additional characterisation and sequencing of all three genomic 
segments completed. Detailed phylogenetic analysis is discussed in section 3.4. 
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Table 3.3 Molecular and serological results of pet rats tested from Oxfordshire 
ID Sex RT-PCR (Ct) Serology 
001 M 32.19 Pos 
002 M 31.25 Pos 
003 M Neg Pos 
004 M Neg Pos 
005 M Neg Pos 
006 M 30.58 Pos 
007 M Neg Pos 
008 M Neg Pos 
009 F 35.14 Pos 
010 F Neg Pos 
011 F 33.09 Pos 
012 F Neg Pos 
013 F 34.36 Pos 
014 F Neg Pos 
015 F 38.57 Pos 
016 F 38.25 Pos 
017 F Neg Pos 
018 F Neg Pos 
019 F Not tested 
020 F Neg Pos 
021 F Neg Pos 
022 F Neg Pos 
023 F Neg Pos 
024 F 36.56 Pos 
025 M Not tested 
 
 
Figure 3.4 RT-PCR results of RNA extracted from pet rat 001 individual organs. (1) 
DNA ladder, (2) PUUV positive control, (3) negative control, (4) brain, (5) bladder, 
(6) heart, (7) kidney, (8) liver, (9) lung, (10) lymph node, (11) pancreas, (12) salivary 
glands, (13) spleen, (14) negative control, (15) DNA ladder and (16) PUUV positive 
control 
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3.3.3 Family follow up 
Following routine epidemiological questioning of the patient it became apparent 
that the partner of the Oxfordshire breeder may have suffered from undiagnosed 
HFRS. In November 2011, one year prior to the previous case, he was hospitalised 
with fever, thrombocytopenia, splenomegaly and AKI. At the time he was diagnosed 
with a virus of unknown aetiology. An archived serum sample from his admission 
was compared to a sample taken in January 2013 and confirmed a hantavirus 
infection with anti-SEOV IgG titre of 1:1000 rising to 1:10,000. The breeder was also 
tested in January 2013 and found to have a low IgG titre of 1:100 against SEOV. The 
partner of the index case had no detectable antibodies against hantaviruses. 
 
3.4  Genomic analysis of UK SEOV strains 
Sequence data was obtained from RNA extracted directly from rat lung tissue. The 
exception being for isolate IR461; viral RNA was extracted from cell culture stocks 
banked in 1984. As is common practice for hantaviruses the strains were name 
after the location from which they were collected, Humber for the Yorkshire 
samples and Cherwell for the Oxfordshire sample. All sequences were submitted to 
GenBank and accession numbers as detailed in Table 3.4. 
Table 3.4 GenBank accession numbers for UK SEOV strains. *previously available via 
GenBank161 
 Humber RN1 Humber RN4 Cherwell IR461 
S JX879769 KM948598 KC626089 AF329388* 
M JX879768 KM948597 KM948593 AF458104* 
L JX879770 KM948596 KM948594 KM948595 
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3.4.1 Comparison of S segment sequences 
The complete S segments of RN1, RN4 (Yorkshire) and 001 (Oxford) were 
determined to be 1768 and 1772 nucleotides (nt) compared with IR461 in between 
with a length of 1769 nt. Each contains a single ORF of 1289 nt (nt 43 – 1332) 
encoding the N protein of 429 aa in length. As expected, the ORFs of all of the 
sequences were found to have a high degree of nucleotide and amino acid 
homology (range from 35 to 38 nt and 1 to 7 aa differences):  
 97.29% nt and 99.77% aa between Yorkshire and Oxford, 
 97.05% nt and 98.6% aa between Yorkshire and IR461, 
 97.21% nt and 98.37% aa between Oxford and IR461. 
 
3.4.2 Comparison of M segment sequences 
The M segments of all three samples and IR461 were found to be 3651 nt in length. 
All contain a single ORF of 3401 nt (nt 47 – 3448) encoding the GPC protein of 1133 
aa. Although a high degree of homology still occurs a greater degree of diversity at 
the nucleotide level can be seen between the ORFs as compared to that between 
the S segments (range from 120 to 161 nt and 9 to 23 aa differences): 
 96.47% nt and 99.2% aa between Yorkshire and Oxford, 
 95.85% nt and 97.97% aa between Yorkshire and IR461, 
 95.27% nt and 98.06% aa between Oxford and IR461. 
 
3.4.3 Comparison of L segment sequences 
The L segments of the Yorkshire samples were found to be 6530 nt in length and 
the Oxfordshire sample 6531 nt. L segment data for IR461 was not available 
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therefore complete sequencing was undertaken in order to have this for 
comparison. It too was found to be 6530 nt in length. All contain a single ORF of 
6455 nt (nt 37 – 6492) encoding the polymerase protein of 2151 aa. Sequence 
homology between the isolate ORFs was comparable to that found for the M 
segments (range from 246 to 278 nt and 19 to 22 aa differences): 
 96.19% nt and 99.12% aa between Yorkshire and Oxford, 
 95.99% nt and 98.98% aa between Yorkshire and IR461, 
 95.69% nt and 99.02% aa between Oxford and IR461. 
 
3.5 Phylogenetic analysis 
Complete nucleotide sequences for each segment were aligned using ClustalW and 
the molecular evolutionary genetics analysis (MEGA5) programme suite was used 
to construct neighbourhood joining trees. The Bootstrap method with 2000 
replicates was chosen for the test of phylogeny with maximum composite likelihood 
selected for the substitution model with uniform rates. Trees were visually rooted 
with the most divergent reference strain TPMV.201 
For all trees, the UK SEOV strains form a distinct cluster (Figures 3.5a, b, c). IR461 is 
suggested as being the ancestral strain for segments M and L. The Chinese strain 
Gou3 forms the basal clade of the S segment tree; complete sequence data of this 
strain is not available for M and L segment analyses. The lack of complete sequence 
data available for M and L segments limits further analysis. 
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Figure 3.5a. Phylogenetic analysis of complete S segment sequences 
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Figure 3.5b Phylogenetic analysis of complete M segment sequences 
 
Page | 76  
 
 
Figure 3.5c. Phylogenetic analysis of complete L segment sequences 
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3.6  Molecular detection of hantaviral RNA in a human sample 
In August 2013, an 11 year old female presented to A&E in Gloucester with a 
headache, malaise, fever and anorexia. Laboratory investigation showed 
haematuria, abnormal LFTs and thrombocytopenia. After learning that pet rats 
were kept in the property where the child was resident, hantavirus serology was 
requested. A serum sample taken four days after onset tested positive for 
hantavirus antibodies: 1:3200 against SEOV and HTNV and 1:320 against DOBV and 
SAAV. Crucially the serum sample was also positive by real-time RT-PCR for SEOV 
and HTNV virus, using an MGB dual probe (CT 37). Further rounds of RT-PCR and 
nested PCR of the L segment confirmed SEOV with 100% homology to the Cherwell 
SEOV strain previously described from pet rats. 
 
 
Figure 3.6 Nested RT-PCR results of RNA extracted from patient sample. (1) DNA 
ladder, (2) negative control, (3-6) replicate patient samples, (7) empty lane, (8) DNA 
ladder, (9) empty lane, (10-11) replicate SEOV positive control 
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3.7  Discussion 
Prior to this study hantaviruses were strongly suspected of causing human disease 
in the UK but yet to be confirmed with only serological data available prior to the 
research described herein. The data presented in this chapter firmly demonstrate 
the existence of a pathogenic SEOV hantavirus in the UK wild and pet rat 
population. Three acute human cases resulting in serious illness were recorded and 
characterised, and follow-up investigation led to the discovery of two new strains of 
SEOV; Humber and Cherwell. A fourth acute case was diagnosed retrospectively. 
Importantly none of the patients had recently travelled outside of the UK.  
 
Noteworthy are the typical symptoms and laboratory markers reported from these 
four cases: all suffered from fever, deranged liver enzymes and thrombocytopenia; 
3/4 also developed AKI. Whilst these markers are likely to be skewed towards 
detection of severe cases they could be used as a preliminary case definition to 
identify patients for hantavirus testing. Early diagnosis is important for improving 
patient outcome; in countries where clinical awareness is high, the need for dialysis 
following hantavirus-induced AKI has fallen to less than 5%.202 Correct and prompt 
diagnosis has also been shown to reduce inappropriate antibiotic treatment in 
Europe.203  
 
The vast majority of hantavirus sequences are from rodent material, with those 
obtained from human cases extremely rare. This is largely due to patient samples 
being taken too late in the course of infection, but also due to low levels of viral 
RNA in blood in humans.204 In this study for the first time, hantavirus genetic 
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material has been directly detected in a specimen from an acutely ill human patient 
in the UK with classic HFRS manifestations and confirmed exposure to carrier 
rodents. Since the material isolated from the patient showed 100% homology to 
the Cherwell strain characterised from pet rats we can be confident that this strain 
of SEOV is pathogenic to humans. 
 
Additionally, whilst SEOV was detected in wild rats, an interesting finding was the 
role of pet rats in hantavirus transmission. Pet rodents are a known risk for 
transmission of zoonotic pathogens 205,206 but this is the first time they have been 
reported as carriers of a hantavirus. Biologically domestic rats are the same as their 
wild counterparts therefore it is not unexpected they have the capability to 
transmit SEOV. From a public health perspective however this is an important 
finding as they are likely to present a greater risk for transmission to their owners 
due to the increased contact time and exposure to potentially infectious excrement 
in confined spaces. Even with strict hygiene measures implemented, the risk is 
unlikely to be eliminated from infected pet animals due to the aerosolisable nature 
of the virus. This is corroborated by the fact that 7/7 contacts with the Yorkshire 
case related to wild rats tested sero-negative whereas 2/3 contacts with the Oxford 
case linked to pet rats were sero-positive, one of whom also was clinically ill with 
typical HFRS disease. 
 
Remarkably most SEOV variants identified thus far are genetically homogeneous 
and closely related to each other with up to 95% nucleotide sequence identity.201 
Analysis of other hantavirus species usually provides clear evidence for origin with 
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geographical clustering as seen for PUUV.207-209 Typically SEOV does not follow such 
a pattern with clusters made up of strains isolated from Korea, Japan and USA. The 
exception here appears to be the UK strains. Phylogenetic analysis showed that the 
UK SEOV strains form a distinct cluster consisting of the three strains from the 
laboratory (IR461), wild (Humber) and pet (Cherwell) rats. The finding that all three 
form such a distinct cluster reduces the likelihood of their having been separately 
introduced into the UK.  
 
Comparison of the nucleotide sequences demonstrates little difference between 
the strains. Humber and Cherwell appear to be more closely related and most likely 
to have evolved from IR461 or a common ancestor yet to be characterised. It 
should be emphasised that, since 1995, no work had been undertaken at PHE 
Porton with SEOV strain IR461. Sequencing of the Yorkshire strain was completed 
before IR461 was retrieved from the archive freezer. None of the sequences 
matched any positive control virus strains handled in the laboratory therefore we 
can be confident no contamination occurred. 
 
For hantaviruses the L segment is typically the most conserved, followed by the M 
segment and then the S segment.210 Interestingly the homology between Humber 
and Cherwell follow the opposite pattern with greater nucleotide and amino acid 
changes seen in the S and M and then the L segment. Sequencing of both rats from 
Humber (RN1 and RN4) was undertaken to investigate any differences between 
individual rats. Minimal divergence was found between the two with only 6 
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nucleotide and no amino acid changes found across all three segments (1 S, 1 M 
and 4 for L- segment). 
 
As this study was focused on detection of hantaviruses in humans and rodents and 
not specific dynamics within hosts quantitative, real-time RT-PCR was not 
employed. None-the-less, comparisons can be drawn; when detected, viral RNA 
appears to be highest within lung, heart, bladder and brain tissue. Specific RNA was 
not consistently detected in all rat tissues. Virus shedding is known to fluctuate due 
to viral replication cycles within rodent hosts.60 Indeed, when investigating the rat 
colony from Oxfordshire all rats tested were found to have a high titre of hantavirus 
reactive antibodies; however, only nine (including two rats from the premises of the 
index case) had detectable viral RNA on the day of sampling. For future testing of 
rats, heart and lung tissue appears to be the best sample types for consistently 
detecting high levels of hantavirus RNA. 
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CHAPTER 4 
Sero-prevalence of hantavirus in potential high risk populations 
 
4.1  Introduction 
Numerous sero-epidemiological studies have shown occupations that include 
human-rodent contact are associated with a higher risk of hantavirus infection.1, 7, 
74, 205,211-213 In comparison to control groups a significantly higher number of sero-
conversions have been demonstrated amongst forestry workers, hunters, farmers 
and military personnel.  
 
During the winter months when My. glareolus seek shelter in buildings, people 
have an increased risk of exposure and infection with PUUV as they come into 
contact with materials contaminated with rodent excreta in confined spaces.212 
Severe disease is more frequently detected in persons between the ages 20-50 
years old with clinical cases in children rare.1 Hantavirus disease has been reported 
in both sexes; however, there is a significantly higher prevalence in males. This 
skew in prevalence for both gender and age is thought to be mainly a result of 
increased occupational exposure.  Unsurprisingly, given the common sequelae 
associated with HFRS, higher sero-conversion rates have been shown in both 
chronic renal failure patients and those suffering from AKI compared to the general 
population.214, 215 
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With SEOV a confirmed cause of HFRS in the UK, further investigations were 
warranted to determine the extent of human exposure to this virus. The main focus 
was in the county of Yorkshire due to the detection of two recent severe acute 
cases there. A sero-epidemiology survey was designed specifically for a risk group in 
this region; farmers.  
 
In respect of the above findings, a serological survey of renal patients in the 
Yorkshire region would also have been an ideal study to undertake within the 
duration of this PhD. However, due to time constraints for ethical approval and a 
similar national survey of renal units being planned following publication of the 
virological findings, this was not possible. Instead an archive of serum samples was 
made available from acute and chronic renal patients who had been admitted to 
Portsmouth hospital. This group of patents provided a reasonable comparison to be 
made between Hull with Portsmouth both being cities having an active port. It also 
provided a snapshot of potential hantavirus seroprevalence in a risk group from 
another UK location and add to knowledge on whether SEOV was restricted to one 
geographical location within the UK.  
 
The final risk group identified, and for which samples were readily available, was 
active British military personnel. The main purpose for inclusion of this group was 
to build a pool of seropositive samples for assay validation at a later stage.  
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Populations tested were: 
1. Farmers and rural residents in North Yorkshire and Humber 
2. British military personnel 
3. Patients with confirmed AKI or CRF in Portsmouth  
 
Screening for hantavirus-specific antibodies was undertaken using a commercially 
available immunofluorescence assay that enabled the simultaneous detection of 
DOB, HTN, PUU, SAA SEO, and SN virus nucleocapsid IgG in human sera. The IFA 
technique has been used extensively for the sero-diagnosis of hantavirus infections, 
screening of animals and selected human populations, and is still the most widely 
used assay. Besides the detection of specific IgG antibodies in serum, IFA can also 
be used to provide an indication for the hantavirus subtype involved by comparing 
serum antibody titres against the respective hantavirus antigens. 
 
In addition, for one of the study populations (Yorkshire farmers) saliva was 
investigated as a suitable sample medium for future sero-prevalence studies. The 
use of saliva is an increasing area of research for diagnostic sampling as it is easy to 
collect, non-invasive to the patient and readily available, with healthy adults 
producing between 500-1500 mL of saliva per day.216 Whilst the predominant 
immunoglobulin isotype in saliva is IgA, IgG is known to be biologically active within 
the oral cavity; it is mainly derived from gingival cervicular fluid and mucosal 
transudate.216,217 A correlation between saliva IgG and serum IgG has been 
demonstrated for many viruses including; human immunodeficiency virus (HIV), 
hepatitis A virus (HAV), hepatitis C virus, Epstein Barr virus (EBV), cytomegalovirus 
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(CMV) and rubella virus.217 No published survey has researched the use of saliva 
collection for detection of IgG levels specific to hantaviruses. 
 
4.2  Sero-prevalence in Yorkshire farmers and rural dwellers  
4.2.1 Study objectives 
 To estimate the sero-prevalence of hantavirus in adults aged 18 years or 
above, who live or work on a farm in North Yorkshire and Humber.  
 Determine whether sero-prevalence varies with age, gender, farm type or 
risk activity. 
 Investigate whether hantavirus specific IgG is detectable in saliva samples 
and comparable to levels of IgG detected in serum. 
 
4.2.2 Study population 
North Yorkshire and the Humber is located in the region of Yorkshire, North East 
England 53°57′30″N, 1°4′49″W (York). The distribution of farm types varies across 
the county: livestock is predominant in the north-west, cereal and general cropping 
in the east/south-east, with the north, north-east and central areas generally more 
fragmented with a mixture of farm types. It has a population of approximately 1, 
700,000 within which there is generally an even gender ratio, with the exception of 
those aged 80+ years where the female: male ratio is ~1.8:1. North Yorkshire has a 
high proportion (24%) of its population over the age of 65 years. The study area 
incorporated the following locations: Craven, East Riding of Yorkshire, Hambleton, 
Harrogate, Hull, North East Lincolnshire, North Lincolnshire, North Yorkshire, 
Richmondshire, Ryedale, Scarborough, Selby and York (Figure 4.1). 
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Figure 4.1 Target areas of North Yorkshire and Humber for inclusion  
 
 
4.2.3 Serological results 
128 volunteers were recruited, with nine excluded from analysis because of 
ineligibility. Of the 119 eligible volunteers sampled and tested, nine (7.6%; 95% CI 
4.0 - 13.8%) had hantavirus specific IgG antibodies detectable at 1:100 dilution. 7/9 
positive sera were considered specific to HTNV and/or SEOV and 2/9 positive sera 
were specific to SNV and/or PUUV.  
 
112/119 disclosed some form of travel outside of the UK in their lifetime; crucially 
the two volunteers whose serum showed cross-reactivity with SNV/PUUV had not 
travelled outside of Europe. While PUUV has been extensively reported as a 
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pathogenic hantavirus in Europe SNV has not, however PUUV and SNV are known 
to serologically cross-react using IFA techniques. The majority of volunteers 
(98/119) disclosed their main or full-time occupation to be farming; the remaining 
volunteers (21/119) merely reside on a farm.  
 
4.2.4 Saliva sampling 
Collection of a corresponding saliva sample was achieved from 117/119 eligible 
volunteers. No other alterations were made to the assay other than sample type. 
From individuals demonstrating a positive serum sample 8/8 of their saliva samples 
were also found to have characteristic positive fluorescence. A subset of saliva 
samples (13) for which their corresponding serum sample was negative were also 
tested to ensure the 8/8 positive saliva samples were indeed true positives and not 
a reaction with standard saliva. None of these 13 saliva sample demonstrated 
characteristic fluorescence.  One saliva sample was unable to be collected from a 
volunteer with positive serum and therefore was not available for testing. A slight 
decrease in fluorescence in comparison to serum samples was noted for all 
samples. In addition specificity for individual hantavirus species was reduced with 
8/8 showing reactivity for HTNV, SEOV and SNV.  
 
4.2.5 Epidemiological analyses 
Table 4.1 details analysis of individual risk variables investigated from the compiled 
questionnaire results. No significant association could be drawn between any 
measured demographic or farm specific variable and sero-status. Analysis was 
limited due to the low number of positive samples and those taken from women, in 
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conjunction with the study population incorporating a convenience rather than 
random sampling; hence results may be both imprecise and subject to bias. 
Therefore care should be drawn when interpreting the results. 
 
All sero-positive individuals reported rodents on their property with 9/9 reporting 
rats and 6/9 mice. Differences in rodent contact may have identified a statistical 
significance protective variable (p > 0.001, OR 0.006) that being reporting the 
presence of rodent during the day. Only 2/9 positive individuals noticed rodents 
during the day compared to 9/9 seeing rodents at night. Further investigation of 
which rodent species are seen highlighted that reporting mice on the farm was also 
associated with decreased risk (p= 0.02, OR 0.1, 95% CI 0.02 to 0.96). In the absence 
of an extremely large population, rats are rarely seen during the day whereas mice 
are less constrained by such population dynamics. Rats predate on mice therefore 
mice are naturally averse to their presence.218 Where you find mice you are less 
likely to find rats. This in turn may decrease the potential for exposure of humans 
to SEOV. This is further supported by volunteers who reported seeing mice on their 
property being less likely to be sero-positive. 
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Category No. positive 
(%) 
No. 
Negative 
No. 
tested 
Odds ratio Confidence  
interval 
P- value* 
Age (years)       
< 30 3 (14.3) 18 21 2.5 0.4 to 13.2 0.2 
≥ 30 6 (6.1) 92 98    
Median 45 51     
Gender       
Male 7 (7.0) 93 100    
Female 2 (10.5) 17 19 1.6 0.1 to 9.2 0.6 
Farmer       
Yes 8 (8.2) 90 98 1.8 0.2 to 82.7 >0.99 
No 1 (4.8) 20 21    
Farm type       
Animal 4 (11.4) 31 35   0.7 
Arable 1 (7.1) 13 14 1.7 0.1 to 88.8  
Mixed 4 (5.7) 66 70 1.9 0.3 to 11  
Farm classification       
Cereal 5 (6.3) 75 80 0.7 0.1 to 3.9 0.7 
Cropping 3 (7.5) 37 40 1.1 0.2 to 5.5 >0.99 
Horticulture 0 4 4 NA   
Pig 1 (5.9) 16 17 0.8 0.02 to 6.7 >0.99 
Poultry 3 (15.0) 17 20 3.0 0.4 to 15.6 0.1 
Dairy 1 (5.6) 17 18 0.8 0.02 to 6.2 >0.99 
Livestock 7 (8.1) 79 86 1.8 0.3 to 18.2 0.7 
Other 0 3 3 NA   
Farm size       
< 500 6 (7.2) 77 83    
≥ 500 3 (9.4) 29 32 2.0 0.5 to 11.5 0.4 
Median 330 296     
Materials       
Silage 9 (9.8) 83 92 NA 0.8 to Inf 0.06 
Bedding 9 (8.6) 96 105 NA 0.4 to Inf 0.4 
Feed 9 (9.1) 90 99 NA 0.6 to Inf 0.2 
Hay 8 (9.3) 78 86 4.2 0.5 to 190.1 0.3 
Timber 7 (6.7) 97 104 0.8 0.1 to 8.4 0.7 
Coal 6 (9.8) 55 61 2.3 0.5 to 15.0 0.3 
Rodents seen       
Mice 6 (5.1) 112 118 0.1 0.02 to 0.96 0.02 
Rats 9 (7.6) 109 118 NA 0.2 to Inf >0.99 
During day 2 (1.7) 117 119 0.006 0.0004 to 0.05 <0.001 
At night 9 (7.6) 109 118 NA 0.2 to Inf >0.99 
Rodent control       
Professional 4 (14.3) 24 28 2.8 0.5 to 14.2 0.2 
Self 5 (5.6) 85 90    
 
Table 4.1 Analysis of factors associated with sero-positivity to hantaviruses 
* Calculated using Fischer’s exact test 
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Postcode information was collected for 115/119 eligible participants allowing 
geographical visualisation of sero-positive individuals; 2/4 volunteers who did not 
provide this information were sero-positive, with both samples identifying exposure 
to PUUV/SNV-like hantavirus. 6/34 districts included in the survey had at least one 
positive sample (Figure 4.2). One of the 6 regions was where an acute case was 
detected, however five did not have any previous information on hantavirus 
occurrence. 
 
 
 
Figure 4.2 Surveyed areas and areas with a minimum of one positive serum sample 
recorded. Stars indicate location of previous acute cases. 
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4.3  Sero-prevalence in British military personnel   
4.3.1 Study objectives 
To determine sero-prevalence of hantavirus in British military personnel deployed 
to Afghanistan. 
 
4.3.2 Study population 
Access was granted to samples collected for general arbovirus surveillance. 
Volunteers were recruited between 2008 and 2011 from either British Army 
regiments or Royal Marines units prior to deployment to Helmand, Afghanistan.  A 
serum sample was taken before and after deployment to determine if sero-
conversion occurred during recent tour. 
 
4.3.3 Serological results 
Over the period of the study March 2008 to October 2011, 453 volunteers gave 
paired samples, (i.e. both pre-deployment and post-deployment samples) which 
were tested for presence of hantavirus antibodies. The sampled population 
consisted of seven Army units deployed across all years and one Royal Marine unit 
deployed in 2010.  Overall 11/453 (2.43%) individuals demonstrated reactive 
antibodies specific to hantaviruses at a dilution of 1:1000. Of those 11, five had 
detectable antibodies in their first sample; therefore, six (1.33%) can be considered 
to have sero-converted during their tour. Separating the two classifications of 
military personnel it is interesting to find Royal Marines appear to have a much 
greater risk of being sero-positive for hantavirus 8/128 (6.25%) compared to 3/325 
(0.92%) Army recruits. No positive samples were detected from tours occurring in 
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the years 2008 and 2009 during which 196 samples were collected compared to 
257 taken during 2010 and 2011. Nine out of the 11 positive samples demonstrated 
a serological cross-reactivity to DOB, HTN and SEO. The remaining two samples 
were indicative of PUU infection. 
 
Table 4.2 Prevalence of sero-conversion against hantavirus in military personnel 
deploying to Afghanistan. Data shown as raw numbers against sample size with 
percentage prevalence in parentheses. Total prevalence is broken down to show 
those that sero-converted on tour (i.e. negative before deployment, positive on 
return) and those who already had detectable antibody prior to deploying. 
 
 
 
 
 
 
 
 
Regiment Year N = N = +ve before tour N = +ve during tour Total +ve 
Army 2008 39 0 0 0 
Army 2009 157 0 0 0 
Army 2010 63 1 (1.59%) 0 1 
Royal Marines 2010 128 4 (3.1%) 4 (3.1%) 8 
Army 2011 66 0 2 (3.0%) 2 
Total  453 5 (1.1%) 6 (1.3%) 11 
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4.4  Sero-prevalence in renal patients   
4.4.1 Study objectives 
To determine sero-prevalence of hantavirus in a subset of renal patients. 
 
4.4.2 Study population 
Patients admitted to Queen Alexandra hospital, Portsmouth, UK with AKI or CRF 
between July and December 2013. Specimens of serum archived after being taken 
for blood-borne virus screening were randomly selected and anonymised by NHS 
staff. They were tested retrospectively at Porton in 2014. Portsmouth is situated on 
the southern coast of Hampshire, South England  50°81′67″N, 1°08′33″W. Figures 
taken from the 2011 Census shows the city has a population of approximately 207, 
000 people with an even gender ratio and a predominance of adults between 24-49 
years old (35%).  
 
4.4.3 Serological results 
From 243 samples tested, 17 (7.0%) demonstrated IgG antibodies reactive against 
hantavirus. Of the 17, 3/41 (7.3%) were from AKI classified patients and 14/202 
(6.9%) from CRF patients. Virtually all, 16/17, were found to show the strongest 
cross reaction to HTN and SEO with only one sample from an AKI patient reactive 
across the entire panel of virus species. Samples were able to be titrated to higher 
dilutions; six at 1:10,000 and 11 at 1:1000.  
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4.5  Discussion 
Three distinctive populations were tested with the common ground of having an 
increased risk for hantavirus specific antibodies compared to the general 
population: farmers, military personnel and patients with renal disease. The sero-
prevalence rates for each were found to be 7.6%, 2.43% and 7.0% respectively.  A 
previous comparable study looking at a subset of the farming population in England 
15 years prior found sero-prevalence for hantaviruses to be 4.7%.143 Although the 
hantavirus sero-positive frequency of this current study appears to be higher at 
7.6%, the previous estimate lies within the 95% confidence interval.  
 
It is interesting that prevalence rates for a separate risk group (patients with renal 
disease) from a region of the country not previously associated with HFRS is nearly 
identical to that for farmers but much higher than a comparable study from 
Northern Ireland which found rates of 2.1% (15/727).145 Due to the lack of 
conclusive data on human infection in the UK, the propensity for subclinical 
infection and the non-specific and diverse symptoms it is likely that clinicians are in 
most cases unaware that hantaviruses are a potential cause of human disease and 
therefore cases are undetected or misdiagnosed as generalised AKI. When an 
infectious cause is considered leptospirosis is the prime candidate.  Hantavirus 
disease is rarely considered part of the differential diagnostic investigations 
requested. 
 
With the Yorkshire region recording some of the highest rates of admission for AKI 
in the UK219 and with recent hantavirus cases resulting in AKI this disease warrants 
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further exploration in renal patients with an unknown aetiology. A 2009 review by 
the National Confidential Enquiry into Patient outcome and Death found evidence 
of one or more complications in patients who died of AKI in 2007. From 564 
patients included in the study 130 exhibited respiratory failure and 35 
haemorrhage. Retrospective analysis also showed the above complications were 
missed in 12 and 3 patients respectively.  
 
As expected, in both the farming and renal groups sero-reactivity was heavily 
skewed towards SEOV and HTNV. Both study areas encompass cities (Hull and 
Portsmouth) with large ports. Two samples belonging to farmers showed reactivity 
to PUUV and SNV. This was not unforeseen; others have reported similar findings 
with three samples reacting to SNV in a study of Swedish farmers.220  It does 
however raise the prospect of another circulating hantavirus in the UK, most likely 
PUUV for which the environmental factors have already been demonstrated to be 
suitable and the reservoir host is widespread.163 However, in contrast to the 
samples from the farming population the samples from renal patients were able to 
be titrated to higher dilutions; six at 1:10,000 and 11 at 1:1000. This is most likely 
due to the exposures being more recent, if not very recent, and the likely cause of 
their admission; therefore antibody titres would be expected to be higher than for a 
population which may have mounted a response decades prior to testing.  
 
Hantavirus disease is not a new hazard to military populations. Several acute cases 
have previously been reported within the British military.154, 155 While sero-
prevalence rates are lower than the other two risk groups it is higher than reported 
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from military populations in other countries. Similar studies have been undertaken 
in Switzerland where they found rates between 0.2 and 1.9%.221 It was interesting 
to look for sero-conversion while troops were on tour and indeed six did convert 
during the sampling period. Five samples were also positive pre and post 
deployment. As it was unlikely to be the first tour for most individuals it is 
impossible to determine if their antibody response was due to exposure in the UK 
or another tour. However, apart from two samples which were almost exclusively 
reactive for PUUV and positive pre and post deployment, the other nine showed 
reactivity for DOBV, HTNV and SEOV. These highly cross-reactive samples will be 
useful for future serological assay validation.  
 
Saliva looks to be promising for determining a simple positive or negative sample 
but appears to be less suitable for identifying individual species. Nonetheless, 
collection of saliva is a convenient and less-invasive sampling method for sero-
surveillance surveys with proven effectiveness for other viruses, and its potential 
use for hantavirus sero-prevalence and screening studies is worth further 
investigation. 
 
Overall these small sero-surveys, in particular those investigating the farming 
community and renal patients, indicate hantavirus is prevalent in risk groups in the 
UK and may be responsible for inducing AKI and CRF in patients in Portsmouth.  
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CHAPTER 5 
Virus isolation and use of inactivated virus in serology assays 
 
5.1  Introduction  
5.1.1 Diagnostic methods for hantaviruses 
Diagnosis of hantavirus infection in humans relies on serological methods, with 
detection of specific IgM antibodies, or a four-fold rise in specific IgG antibodies 
from paired samples, confirming an acute infection.222 No detection of IgM or 
comparable levels of IgG in paired samples taken greater than two weeks apart 
indicates past infection, with specific antibodies considered to be life-long.  
 
Several commercial assays are available for hantavirus serological testing but they 
are expensive, and mostly based on IF methods that use fluorescein isothiocyanate 
(FITC)-labelled monoclonal antibodies (MAbs) or an ELISA targeting one specific 
hantavirus species.  
 
Detection of viral antigens using IFAs has been employed since the 1970s and if 
performed correctly provides reasonable specificity and sensitivity. However, such 
assays are demanding, require expertise for interpretation of test results, and rarely 
fit easily into high-throughput laboratory workflows. ELISA’s were also developed in 
the 1970s and have the advantage of being comparatively cheap, highly sensitive 
due to the enzymatic detection properties, and high throughput.  
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For both types of assay, live, and inactivated (irradiated) whole virus can be used 
but production of these requires ACDP level 3 facilities and irradiation requires 
specialist and costly equipment. Instead of whole virus, the majority of commercial 
assays have relied on recombinant hantavirus nucleoprotein expressed by 
baculoviruses, Escherichia coli, vaccinia virus or yeast systems. These have the 
benefit of mass production of antigen outside of high containment facilities.  
 
5.1.2 Current diagnostic methods employed at PHE Porton for hantaviruses  
Public Health England, Porton, is the Reference Laboratory for hantavirus testing in 
the UK, a commercially available IFA detecting specific IgG is the main tool for 
clinical diagnosis. Virus isolation and focus reduction neutralisation testing (FRNT) 
are techniques not routinely undertaken in recent times at Porton and such 
protocols needed developing for further characterisation of positive samples.  
 
5.1.3 Diagnostic challenges with hantaviruses 
Viral isolation has traditionally been the ‘gold standard’ for the diagnosis of human 
infection but as it requires a high level of expertise, is labour intensive and slow, it is 
progressively being replaced by rapid molecular methods. Isolation of hantaviruses, 
in particular, is rarely successful but it is necessary to investigate antigenic change, 
confirm virus viability, perform animal studies and assess antiviral susceptibility. 
Efforts are enhanced by using fresh tissue from reservoir host animals as noted in 
Chapter 4.  
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It should be emphasised that given the length of time required for isolation of 
hantaviruses the use of this technique is of limited benefit to immediate patient 
management. Virus isolation is of value to longer term clinical research and to 
contribute to molecular epidemiological and evolutionary knowledge on circulating 
hantavirus species. As discussed in Chapter 1 different hantavirus strains are 
responsible for a variety of clinical outcomes therefore it is useful to identify the 
causative species of hantavirus infections to improve clinical responses to patient 
care. Rapid molecular techniques, such as RT-PCR, are able to provide a prompt, 
reliable and specific differential laboratory diagnosis but the effectiveness of the 
technique is constrained by the short term viraemia produced by hantavirus 
infection. 
 
In the absence of virus isolation or molecular detection, a better indication of the 
causative hantavirus species for human infection can be gained through FRNT. 
Comparison of levels of neutralising antibody against a panel of hantaviruses 
identifies the species the antibodies are most reactive against. The main 
disadvantage of this technique is it may lead to the inaccurate classification of a 
novel hantavirus. It is also a burdensome and slow technique again requiring ACDP 
level 3 facilities and is therefore rarely used for diagnostic purposes. Furthermore, 
the best results are obtained with convalescent serum taken a minimum of 3 weeks 
after onset of illness which again is of little benefit to acute patient management. 
The ideal situation would be for a high throughput serological assay to be 
developed which could confidently differentiate between different hantavirus 
species.  
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5.1.4 Aims of the Chapter 
The aims were to generate a cell culture isolate of a UK SEOV strain and to use this 
virus for the development of antigen for future serological assays.  
 
5.2  Isolation of Seoul virus strain Humber 
Lung tissue of wild rat number 1 from Yorkshire (RN1) was homogenised in sterile 
PBS and inoculated on confluent Vero E6 cells. In the beginning cultures grown at 
37 °C were passaged by splitting 1:5 every 5-7 days when cells looked over-
confluent. This protocol was amended to cultures being grown at 35.5 °C, then 
splitting every 10-14 days between 2 and 5 mL of inoculated cells were added to 
60% confluent fresh cells. Real-time RT-PCR and IFA was performed for each split 
until at least 8 passages had been performed.  
 
Cultures were discarded after this time if no positive signals were detected. Several 
attempts were made including: homogenisation of different tissue types in PBS, 1% 
BSA solution and DMEM; inoculations with a range of tissue dilutions from neat to 
1:1000; and, a range of inoculation times from 60 min to overnight.  
 
At no time was viral growth successful using RN1 samples despite strong molecular 
signals from neat tissue. Attempts were then focused on tissue samples from wild 
rat RN4. From the first passage infected Vero E6 cells showed positive IF staining to 
a commercial monoclonal antibody (Progen, Germany) against the nucleocapsid 
protein of SEOV R22 strain after ten days in culture. After a further three passages 
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all cells demonstrated positive staining (Figure 5.1), the cells were harvested and 
the virus was considered isolated.  
 
 
 
Figure 5.1 Vero E6 cells infected with Humber virus (top picture) showing positive 
FITC staining and negative control Vero E6 (bottom picture). Viewed at total 200x 
magnification using EUROStar III plus microscope 
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The isolate was designated Seoul hantavirus, strain Humber. Negative Vero E6 cells 
showed no specific staining.  
 
From reviewing the literature of successful isolations for hantaviruses and 
knowledge gained from these isolation attempts the protocol detailed in Chapter 2 
section 2.4 is the method of choice for future attempts. 
 
5.3  Unsuccessful isolations 
The isolation protocol detailed in Chapter 2 was utilised for rats 001 and 002 from 
Oxfordshire. Homogenised brain, heart, lung and liver tissue were attempted with 
no success.  
 
After serological testing and one aliquot taken for molecular testing there was no 
sample available from the only RT-PCR positive patient sample. Further serum and 
urine samples taken had no detectable hantavirus RNA and therefore culture was 
not attempted.  
 
5.4  Quantification of Humber virus 
The plaque assay technique223 was attempted to quantify virus in isolation material 
and for future use with positive serum in PRNT.  Despite following the protocol 
exactly, plaques were never successfully visualised. Different concentrations of 
DMSO, various overlay substrates (Agarose, CMC and Avicel), and a range of 
inoculation times and infection times were tried. Attempts were also unsuccessful 
for HTNV virus. In particular, due to the length of time hantaviruses require to 
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grow, cell monolayers were negatively affected and it was impossible to 
differentiate between plaques caused by virus and normal cell death due to over-
confluence. As hantaviruses do not produce cytopathic effects in Vero E6 cells, it is 
unsurprising the plaque assay technique is not efficacious. In current times the 
focus forming assay (FFA) is the method of choice. The FFA is a variant of the plaque 
assay beneficial for quantifying viruses that do not lyse infected cells. Results of the 
FFA are expressed as focus forming units per millilitre, or FFU/mL. Using the same 
FITC-MAb as for IFA, the FFA demonstrated 1.1 x 106 FFU per 1 mL for Humber 
virus. 
 
5.5  UV inactivation of Humber virus 
Stocks of Humber virus at 1.1 x 106 FFU per 1 mL were successfully inactivated 
(Figure 5.2a and b) using the method described in the literature135 and in Chapter 2. 
Even at neat concentration, no positive staining for viable virus following 
inoculation with inactivated samples was visible. Native Humber virus was used as 
positive control. Once inactivation was proven to be effective stocks were removed 
from the CL3 laboratory and handled on the bench under CL2 conditions. 
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Figure 5.2a. In-house IFA showing positive staining for native HUMV virus and no 
staining for UV inactivated virus at neat, 1:10 and 1:100 dilutions. Viewed at total 
200x magnification. 
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Figure 5.2b. In-house IFA showing positive staining for native HUMV virus and no 
staining for UV inactivated virus at dilutions 1:1000 and 10,000. Viewed at total 
200x magnification. 
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5.6  Inactivated whole virus as antigen in an ELISA 
The results of the UV inactivate virus as antigen using the method described in 
Chapter 2 are demonstrated in Figure 5.3. Two serum samples confirmed positive 
for hantavirus specific antibodies, SEOV and PUUV, via IFA were tested at 1:100 and 
1:1000 dilution. UV-inactivated hantaviruses, including the Humber strain isolated 
during this study, were coated to the plate in a dilutions 1:10, 1:100, 1:1000 and 
1:10,000.  In addition a negative serum sample and an equivocal sample were 
tested at the same dilutions.  
 
ELISA development was initially hampered by the lack of whole virus sticking to the 
plate during coating. A variety of buffer types and coating incubation times and 
temperatures were trialled. Overnight coating at 4 °C in carbonate-bicarbonate 
buffer (pH 9.6) was found to be the most successful. 
 
OD values for the final method tested during this study are shown in Figures 5.3a 
and b. Both visual and OD values demonstrate reactivity for positive serum samples 
in comparison to little reactivity for the negative and equivocal serum. More 
detailed analysis and refinement was not possible at this time, as time constraints 
prevented further work-up. However these preliminary results indicate UV-
inactivated hantavirus is a potential antigen for use in an ELISA format.  
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 SEOV HTNV DOBV PUUV SNV TULV 
 1 
100 
2 
1000 
3 
100 
4 
1000 
5 
100 
6 
1000 
7 
100 
8 
1000 
9 
100 
10 
1000 
11 
100 
12 
1000 
A 
10 
0.137 0.025 0.182 0.182 0.281 0.115 0.182 0.076 0.140 0.181 0.328 0.500 
B 
100 
0.015 0.047 0.171 0.171 0.388 0.232 0.171 0.152 0.187 0.271 0.158 0.306 
C 
1000 
 
0.064 0.278 0.216 0.216 0.469 0.419 0.216 0.116 0.370 0.126 0.273 0.223 
D 
10k 
0.096 0.095 0.417 0.417 0.592 0.566 0.417 0.276 0.383 0.151 0.425 0.165 
E 
10 
0.039 0.096 0.375 0.537 0.369 0.364 0.473 0.501 0.117 0.080 0.140 0.136 
F 
100 
0.062 0.247 0.520 0.510 0.659 0.190 0.691 0.219 0.191 0.137 0.160 0.126 
G 
1000 
0.075 0.159 0.559 0.637 0.251 0.190 0.366 0.435 0.344 0.317 0.219 0.086 
H 
10k 
0.047 0.041 0.291 0.204 0.262 0.268 0.345 0.297 0.349 0.173 0.323 0.282 
 
Figure 5.3a. Adjusted (minus negative values in Figure 5.3b rows A to D) OD values 
of ELISA plate incubated with patient serum reactive for SEOV (rows A to D of plate) 
and patient serum reactive for PUUV (rows E to H plate). X axis shows hantavirus 
species coated on plate and patient sera dilution. Y axis shows the dilution of the 
virus coated onto the plate. 
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 SEOV HTNV DOBV PUUV SNV TULV 
 1 
100 
2 
100
0 
3 
100 
4 
100
0 
5 
100 
6 
100
0 
7 
100 
8 
100
0 
9 
100 
10 
100
0 
11 
100 
12 
100
0 A 
10 
0.10
8 
0.11
1 
0.12
3 
0.10
0 
0.09
6 
0.11
6 
0.10
4 
0.12
3 
0.15
7 
0.11
3 
0.11
1 
0.11
1 
B 
100 
0.12
2 
0.14
5 
0.14
3 
0.10
5 
0.11
4 
0.12
8 
0.13
4 
0.09
8 
0.12
5 
0.13
2 
0.11
2 
0.10
5 
C 
100
0 
 
0.10
5 
0.12
2 
0.11
3 
0.10
6 
0.11
1 
0.10
3 
0.11
6 
0.10
7 
0.11
3 
0.10
2 
0.10
0 
0.10
7 
D 
10k 
0.10
4 
0.12
2 
0.11
1 
0.14
8 
0.11
9 
0.10
3 
0.11
4 
0.10
1 
0.12
4 
0.12
5 
0.10
4 
0.11
8 
E 
10 
0.11
7 
0.13
0 
0.16
4 
0.12
6 
0.12
4 
0.11
4 
0.10
8 
0.11
8 
0.12
5 
0.09
1 
0.11
1 
0.09
2 
F 
100 
0.11
3 
0.12
7 
0.13
6 
0.10
6 
0.13
1 
0.10
5 
0.11
3 
0.13
5 
0.18
2 
0.09
3 
0.11
4 
0.09
3 
G 
100
0 
0.13
4 
0.11
4 
0.15
1 
0.11
8 
0.16
5 
0.13
2 
0.15
7 
0.11
6 
0.22
1 
0.12
6 
0.13
7 
0.10
0 
H 
10k 
0.17
3 
0.11
2 
0.17
2 
0.12
0 
0.17
5 
0.10
6 
0.17
2 
0.12
9 
0.18
2 
0.10
4 
0.16
4 
0.10
9 
 
Figure 5.3b. OD values of ELISA plate incubated with negative patient serum (rows 
A to D of plate) and an equivocal human sample with weak IFA signal but 
considered negative (rows E to H plate). X axis shows hantavirus species coated on 
plate and sera dilution. Y axis shows the dilution of the virus coated onto the plate. 
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5.7  Ultracentrifugation of Humber virus 
Various methods were trialled in order to purify and concentrate HUMV as use for 
future antigen rather than using crude cell lysate stocks. Maximum centrifugation 
speed and time was balanced against protecting the virus to maintain infectivity. 
The method described in Chapter 2 was deemed to be the most successful and in-
house IFA confirmed purified virus was still capable of infecting E6 cells. 
 
5.8  Discussion 
In addition to the molecular evidence for a SEOV, presented in Chapter 3, herein 
the chapter reports the successful isolation of the SEOV strain Humber from wild R. 
norvegicus trapped in Yorkshire; thereby proving the presence of an infectious 
SEOV in the UK. This isolate is certified mycoplasma free and available to accredited 
laboratories via the National Collection of Pathogenic Viruses (catalogue no. 
1211221v). The reason why virus could only be cultured from RN4 tissue and not 
RN1 is unknown as both yielded comparably strong RT-PCR signals. It is conceivable 
that RN1 was trapped earlier in the night than RN4 and therefore had more time for 
tissue and virus degradation before being collected and frozen the following 
morning. 
 
Despite numerous attempts with SEOV strain Cherwell, no isolation was made. This 
is most likely a direct adverse effect of the Pentobarbitone used to humanely 
euthanize the pet animals as tissue samples yielded strong RT-PCR signals and 
samples were transported and handled using identical methods to those from 
Yorkshire. Pentobarbitone is an alkylating agent which in high concentrations will 
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interfere with viral replication and protein synthesis.  It is unfortunate there was 
not enough sample available for an isolation attempt from the RT-PCR positive 
patient, however given the few amino acid differences between Humber and 
Cherwell it was concluded that the two are antigenically identical thus would not 
impact on future assay development. 
 
To quantify virus in aliquoted samples for future FRNT testing an FFA protocol was 
adopted. Focus forming assays have the drawback of incurring a higher cost due to 
the conjugated antibody required than the plaque assay but the substantial 
advantage of a shorter time for results. Hantaviruses are slow-growing and if the 
assay relies on cell lysis it will be between 10 and 14 days before results are 
available. For this study infected cells for the FFA were incubated for 7 days but 
preliminary data indicates this can be reduced and work will continue to determine 
the optimum time this can be achieved. Seven days is still a long period of time for 
acute diagnosis of infection and is unlikely to be routinely requested by clinicians. 
Instead it is useful to quantify material for research purposes and for use in FRNT 
for a better indication of causative hantavirus species if this is required once a 
diagnosis is made.  It will also aid epidemiological tracing and identification of the 
rodent source of infection. 
 
It is encouraging that the published protocol for inactivating hantaviruses using UV 
irradiation was reproducible. For safety reasons and to comply with internal risk 
assessments, proof of inactivation was required.  Even neat virus stocks were 
inactivated as demonstrated no evidence of positive staining following culture. As 
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apparent for native virus (Figure 5.2a shows decreased staining for neat virus 
compared to virus diluted 1:10) if hantaviruses are added to cultured cells at too 
high a concentration defective particles are produced and virus proliferation 
decreased. A dilution series of both native and inactivated virus was performed to 
ensure inactivation was successful and lack of staining was not as a result of viral 
self-inhibition. 
 
The viral antigens for the IgG ELISA were, respectively, a whole-virus preparation of 
UV inactivated DOBV, HTNV, PUUV, SEO, SNV and TULV from cell culture. The cell 
lysate was chosen over purified virus as this method shows less background than 
purified antigen224 however ultracentrifuged antigen may be trialled in the future to 
compare if this improves sensitivity and adherence of the antigen to the micro 
wells.  ELISAs using native whole virus have also been shown to have higher 
sensitivity than those employing partial or recombinant antigen although 
conversely may show an increase in cross-reaction across the hantavirus species.226-
227 The reactive pattern of adjusted OD values for both SEOV positive and PUUV 
positive serum is similar. Interestingly, OD values increase in parallel with virus 
dilution with the highest values often recorded for virus dilution at 1:1000 and 1:10, 
000. Perhaps similar to results seen for FFA, too high a concentration of virus 
produces viral interference. When bunyaviruses reach a certain concentration they 
produce defective viral particles rather than replicating whole virus.47  
 
Protein values were retrospectively obtained for each hantavirus to attempt to 
understand the difference in cross-reactivity of the ELISA plate and explain why the 
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serum reactive for SEOV via IFA reacted so weakly with the HUMV coated wells. 
Total protein concentration was found to be similar so did not explain the weak 
reaction for HUMV however they did indicate protein levels were too high 
(between 3.8 and 5.0 mg/mL). While this is total protein and not necessarily pure 
viral protein it is far higher than that which is ideal for use in ELISA plates and the 
concentration would be greatly diluted for future assay work-up. Too high a 
concentration of antigen can negatively affect coating leading to oversaturation of 
the plate which results in inhibition of antibody binding.  
 
It may be possible to reduce such cross-reactivity and interference with full 
validation and ELISA work-up, including dilution series of optimum antigen, 
antibody and virus concentration. Once the chosen antigen has been fully 
characterised further refinements to the ELISA may include progression to a 
capture ELISA. This has the advantage of allowing quantification of antibody in the 
serum sample.  
 
Any future development should be mindful that the ELISA is intended to provide 
laboratory differential diagnostic capability, and that cross-reactivity between 
different virus antigens may, in fact, be a useful property. The initial ELISA test 
would ideally pick up all strains of hantavirus and simply provide a sensitive and 
specific positive or negative result. ELISAs are rarely suitable for sero-typing when 
such cross-reactivity between virus species exists. Characterisation of the exact 
hantavirus species can then be undertaken on the vastly reduced number of 
positive samples rather than on all suspected samples.  
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The purpose of this crude ELISA and use of UV inactivated virus as antigen was to 
provide a proof of principle. This limited data confirms the antigen is reactive to 
positive serum containing hantavirus specific antibodies compared with negative 
hantavirus control serum. If time had permitted it would have been interesting to 
mix the UV inactivated virus strains to determine their combined reactivity against 
different hantavirus serum antibody profiles. UV works as an inactivation method 
by damaging viral nucleic acids resulting in cross linkage of pyrimidine bases; prior 
to this test it was not known if the cross-linkage would interfere with sero-
reactivity.  
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CHAPTER 6 
Discussion and Conclusion 
 
Previous research between the 1970s and 1990s had provided strong serological 
evidence in human patients for at least one hantavirus species circulating in wild 
rodents and one hantavirus associated exclusively with laboratory rats. This PhD 
aimed to build on these findings and through use of a combination of molecular and 
serological techniques characterise and confirm a hantavirus responsible for 
current human renal disease in the UK. 
 
6.1  Hantavirus as a confirmed human pathogen in the UK 
6.1.1 Seoul hantavirus 
The investigation of rodents linked to acute human cases of HFRS during this study 
led to the isolation and characterisation of one SEOV strain (Humber) from wild R. 
norvegicus and molecular characterisation of a second closely related SEOV strain 
(Cherwell) from pet R. norvegicus. Partial sequence data, obtained from a human 
serum sample, matched with 100% homology to the L segment of the Cherwell 
strain firmly establishing this SEOV is pathogenic to humans. Within the timeframe 
of this PhD a pathogenic hantavirus circulating in wild and pet rats has been 
confirmed in the UK.  
 
Seoul virus is a known cause of renal disease in Asia but data on its role in causing 
renal disease in Europe are scarce. Following the publication of the UK findings 
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presented in this thesis the first molecularly confirmed human case of SEOV 
infection was reported from France.228 In addition multiple SEOV positive wild R. 
norvegicus were detected in the Lyon region of France.229 Further afield a highly 
similar SEOV has been recently reported from wild R. norvegicus in New York.230 
The findings from New York reported by Firth et al. (2014)230 are of particular 
interest as not only is the Baxter strain closely related to HUMV but the authors 
estimated it was introduced to the region 3-16 years prior. It seems a logical step to 
perform similar analysis of the three UK strains: HUMV, CHEV and IR461. While it is 
tempting to speculate IR461 is the ancestral strain from the interpretation of the 
phylogenetic trees and the fact that IR461 was proven to be introduced via 
imported rats from Belgium via Japan (simultaneously resulting in human infection 
in both countries); molecular clock analysis would provide more substantial 
evidence to confirm this.  
 
6.1.2 Reservoir hosts 
While it was not surprising to identify wild rats as carrier hosts, the involvement of 
pet rats was unexpected and appears to be the first report of pet animals 
responsible for transmission of a hantavirus to humans. A separate sero-study that 
followed the initial discovery of the involvement of pet rats in human disease was 
undertaken as part of a public health investigation led by Public Health England. 
Between October 2013 and June 2014 people with likely exposure to wild and pet 
rats were sampled and tested for hantavirus antibodies. The key finding of this 
study was 32.9% (26/79) of the sera from pet rat owners were found to have 
hantavirus antibodies when tested using the commercial IF assay described in 
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Chapter 2. The strongest reactivity were observed against SEOV antigen. This 
implies SEOV is circulating within pet rat populations in the UK and could present a 
significant health risk to owners, breeders, veterinarians and retail suppliers who 
handle these rodents.  
 
It was not possible to access medical records for those rat owners who were 
seropositive. The next step therefore would be to understand what proportion of 
the 33% were ever clinically ill or is there a subset of people who seroconvert but 
have subclinical infection. If the majority of pet rat owners develop AKI then the 
situation requires more attention than if only a marginal number of owners develop 
severe disease. There is a delicate balance required for future investigations as 
these animals are treasured pets and/or a source of income. An appropriate testing 
strategy needs to be devised to identify positive animals in both the trade and 
domestic setting. 
 
Following the publication of the UK pet rat findings, researchers conducted a 
subsequent investigation in Sweden and demonstrated SEOV positive rats in a 
colony which included a rat imported from the UK. 230 This demonstrates such 
findings are again not limited to the UK and the virus can be imported and exported 
via the pet rat trade.   
 
6.2  Circulation of other hantavirus species 
The results presented in this thesis alongside the subsequent findings of SEOV in 
France, Sweden and the USA continues to provide evidence for SEOV as a pathogen 
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outside of its origin in Asia.  As shown two decades prior, it is important to include 
Seoul antigen in the panels for hantavirus screening in Europe.145  The majority of 
sero-conversions in the Northern Ireland study would have been wrongly classified 
as negative had the SEOV R22 antigen not been utilised. This is however not to 
suggest SEOV is the only hantavirus of importance in the UK.  
 
There is strong evidence for an additional hantavirus species circulating in the UK. 
Two of the farmers investigated in Chapter 4 demonstrated reactive antibodies to 
SNV and PUUV, not SEOV. In addition, three sero positive sera from the public 
health investigation mentioned in section 6.1.2 were reactive to other hantaviruses: 
two reactive against DOBV antigen and one reactive against PUUV. This is in 
contrast to pet rat owners which only demonstrated seropositivity for SEOV and 
HTNV.  
 
Research by others in the UK may have in part alluded to this second hantavirus 
species. Pounder et al. (2013)233 provided preliminary findings of a hantavirus 
detected in a Microtus agrestis (field vole) in Northern England. Limited molecular 
data was recovered but enough to indicate a hantavirus and subsequent serology 
was cross reactive for PUUV. As the species of vole tested was not My. glareolus it 
is unlikely to be PUUV but antigenically a closely related hantavirus species.23 
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6.3  Clinical definition and raised awareness 
6.3.1 Case definition 
Compiling the clinical findings of the most recent UK cases discussed in Chapter 3 
and those reported previously in the literature, SEOV hantavirus infection should be 
suspected and tested for when the following symptoms and laboratory markers are 
present in conjunction with relevant epidemiological exposure to wild or pet rats: 
 Abdominal pain 
 Fever 
 Chills 
 Headache 
 Vomiting 
 Elevated creatinine 
 Thrombocytopenia 
 
6.3.2 Raised awareness 
Throughout this study findings have been disseminated via peer-reviewed 
publication, press releases and through oral presentations at national and 
international conferences. Awareness of hantavirus as a cause of AKI has been 
raised among the UK medical community. This is evident by the rise in requests for 
hantavirus testing through RIPL, PHE Porton. 
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Table 6.1 Number of hantavirus IFA tests performed at PHE Porton. 
Year No. of IFA tests 
2010 28 
2011 41 
2012 271 
2013 256 
2014 259 
 
6.4  Future work 
The findings presented in this thesis have highlighted several areas for future 
research; in particular further investigation is necessary to clarify the samples with 
reactivity to hantavirus species other than SEOV (sero-results detailed in Appendix 
II). The FFU technique discussed in Chapter 5 could easily be expanded to other 
hantavirus species and be used for the titration of clinical samples via FRNT by the 
hantavirus reference laboratory at PHE, Porton. This would aid epidemiological and 
outbreak investigations when molecular data is not available.  
 
Completion of the UV inactivated virus ELISA which would pick up sero-conversion 
to all clinically relevant hantavirus species would provide a useful first-line 
screening assay for reference laboratories. The current commercially available 
assays are prohibitively expensive, only target one or a limited number of 
antigenically related hantavirus species and are too labour intensive for large scale 
screening studies or busy reference laboratories. 
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Considering the prevalence of hantavirus infection in pet rats and the propensity of 
the fancy rat community in showing and sharing animals potentially chronically 
infected, it is impracticable to think SEOV will be eradicated in the UK. Within such 
a community, control and prevention strategies are challenging. They range from 
the provision of awareness advice to vaccine development. The introduction of any 
vaccine in the UK could be directed to a number of risk groups such as pet rat 
owners, farmers, military personnel and veterinarians. As previously mentioned in 
Chapter 1 there are vaccines currently on the Asian market 120, 121 but these are 
unlikely to ever gain approval for use in Europe as they are not manufactured to EU 
regulatory standards. The DNA based vaccine currently at clinical trial stage in USA 
is based on PUUV and ANDV and therefore will not guarantee protection against 
SEOV.122, 123 A recently developed recombinant candidate vaccine using an 
attenuated poxvirus vector, Modified Vaccinia virus Ankara, has been shown to be 
highly effective for another Bunyaviridae - Crimean-Congo haemorrhagic fever 
virus.232 This use of this methodology for production of a hantavirus vaccine has 
potential.  
 
6.5 Conclusion 
Knowledge on hantavirus as a cause of AKI in the UK requires further 
characterisation. The findings presented in this thesis provide conclusive evidence 
for the presence of SEOV in the UK and a starting point for future investigations in 
the UK into human disease and enzootic cycles in rodent hosts.  
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